WO2000031306A2 - Multiplex amplification of short tandem repeat loci - Google Patents

Multiplex amplification of short tandem repeat loci Download PDF

Info

Publication number
WO2000031306A2
WO2000031306A2 PCT/US1999/027876 US9927876W WO0031306A2 WO 2000031306 A2 WO2000031306 A2 WO 2000031306A2 US 9927876 W US9927876 W US 9927876W WO 0031306 A2 WO0031306 A2 WO 0031306A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
loci
locus
amplified
primers
Prior art date
Application number
PCT/US1999/027876
Other languages
French (fr)
Other versions
WO2000031306A9 (en
WO2000031306A3 (en
Inventor
James W. Schumm
Cynthia J. Sprecher
Original Assignee
Promega Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22737974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000031306(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Promega Corporation filed Critical Promega Corporation
Priority to AU31034/00A priority Critical patent/AU774626B2/en
Priority to CA002352042A priority patent/CA2352042A1/en
Priority to BR9915597-4A priority patent/BR9915597A/en
Priority to JP2000584113A priority patent/JP5456950B2/en
Priority to EP99965030A priority patent/EP1135530B1/en
Priority to ES99965030T priority patent/ES2394070T3/en
Publication of WO2000031306A2 publication Critical patent/WO2000031306A2/en
Publication of WO2000031306A3 publication Critical patent/WO2000031306A3/en
Priority to HK01107340.1A priority patent/HK1036638A1/en
Publication of WO2000031306A9 publication Critical patent/WO2000031306A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Definitions

  • the present invention is generally directed to the detection of genetic markers in a genomic system.
  • the present invention is more specifically directed to the simultaneous amplification of multiple distinct polymorphic genetic loci using the polymerase chain reaction or other amplification systems to determine, in one reaction, the alleles of each locus contained within the multiplex system.
  • DNA typing is commonly used to identify the parentage of human children, and to confirm the lineage of horses, dogs, other animals, and agricultural crops. DNA typing is also commonly employed to identify the source of blood, saliva, semen, and other tissue found at a crime scenes or other sites requiring identification of human remains. DNA typing is also employed in clinical settings to determine success or failure of bone marrow transplantation and presence of particular cancerous tissues. DNA typing involves the analysis of alleles of genomic DNA with characteristics of interest, commonly referred to as "markers". Most typing methods in use today are specifically designed to detect and analyze differences in the length and/or sequence of one or more regions of DNA markers known to appear in at least two different forms in a population.
  • polymorphism Such length and/or sequence variation is referred to as "polymorphism.” Any region (i.e. "locus") of DNA in which such a variation occurs is referred to as a “polymorphic locus.”
  • locus Any region (i.e. "locus") of DNA in which such a variation occurs is referred to as a “polymorphic locus.”
  • locus Any region (i.e. "locus") of DNA in which such a variation occurs is referred to as a “polymorphic locus.”
  • the methods and materials of the present invention are designed for use in the detection of multiple loci of DNA, some or all of which are polymorphic loci.
  • markers which are sufficiently polymorphic with respect to length or sequence have long been sought for use in identity applications, such as paternity testing and identification of tissue samples collected for forensic analysis.
  • identity applications such as paternity testing and identification of tissue samples collected for forensic analysis.
  • the discovery and development of such markers and methods for analyzing such markers have gone through several phases of development over the last several years.
  • the first identified DNA variant markers were simple base substitutions, i.e. simple sequence polymorphisms, which were most often detected by Southern hybridization assays.
  • DNA variant markers designed to be used to analyze restriction endonuclease-digested DNA with radioactive probes, see: Southern, E. M. (1975), J. Mol. Biol. 98(3):503-507; Schumm, et al. (1988), American Journal of H ⁇ man Genetics 42:143-1 59; and Wyman, A. and White, R. (1980) Proc. Natl. Acad. Sci, U.S.A. 77:6754-6758.
  • VNTR variable number of tandem repeat
  • VNTRs 70 bases in length, with shorter core repeat sequences referred to as "minisatellite” repeats and longer repeats referred to as VNTRs. Different individuals in a human population contain different numbers of the repeats.
  • the VNTR markers are generally more highly polymorphic than base substitution polymorphisms, sometimes displaying up to forty or more alleles at a single genetic locus.
  • restriction enzyme digestion and subsequent Southern hybridization analysis are still required to detect and analyze most such markers.
  • Amplifiable VNTR loci were discovered, which could be detected without the need for Southern transfer.
  • the amplified products are separated through agarose or polyacrylamide gels and detected by incorporation of radioactivity during the amplification or by post-staining with silver or ethidium bromide.
  • PCR can only be used to amplify relatively small
  • STR loci are similar to amplifiable VNTR loci in that the amplified alleles at each such locus may be differentiated based on length variation. Generally speaking STR loci are less polymorphic at each individual locus than VNTR loci. Thus, it is desirable to amplify and detect multiple STR systems in a single amplification reaction and separation to provide information for several loci simultaneously. Systems containing several loci are called multiplex systems and many such systems containing up to 1 1 separate STR loci have been described. See, e.g., Proceedings: American Academy of Forensic
  • Amplification protocols with STR loci can be designed to produce small products, generally from 60 to 500 base pairs (bp) in length, and alleles from each locus are often contained within a range of less than 100 bp. This allows simultaneous electrophoretic analysis of several systems on the same gel or capillary electrophoresis by careful design of PCR primers such that all potential amplification products from an individual system do not overlap the range of alleles of other systems. Design of these systems is limited, in part, by the difficulty in separating multiple loci in a single gel or capillary. This occurs because there is spacial compression of fragments of different sizes, especially longer fragments in gels or capillaries, i.e., commonly used means for separation of DNA fragments by those skilled in the art.
  • CODIS Combined DNA Index System
  • the thirteen CODIS STR loci are HUMCSF1 PO, D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D1 8S51 , D21 S1 1 , HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 .
  • Both VNTR and STR marker data are currently maintained in the CODIS database. (See, e.g. Niezgoda, Stephen in Second Annual Conference on DNA Forensics. supra).
  • the materials and methods of the present method are designed for use in multiplex analysis of particular polymorphic loci of DNA of various types, including single-stranded and double-stranded DNA from a variety of different sources.
  • the present invention represents a significant improvement over existing technology, bringing increased power of discrimination, precision, and throughput to DNA profiling for linkage analysis, criminal justice, paternity testing, and other forensic, medical, and genetic identification applications.
  • an object of the present invention to provide a method and materials for the simultaneous amplification of sets of loci, which include multiple distinct polymorphic short tandem repeat (STR) loci, in a single multiplex reaction, using PCR or other amplification systems in combination with gel electrophoresis, capillary electrophoresis or other separation and detection methods to analyze and compare the relative lengths of the alleles of each locus amplified in the multiplex reaction.
  • Multiplex analysis of the sets of loci disclosed herein has not been previously described in the prior art. There has also not been any previous description of the sequences for many of the primers disclosed herein below, all of which are shown to be useful in multiplex amplification of the sets of loci disclosed.
  • the present invention is directed to a method and materials for simultaneously analyzing or determining the alleles present at each individual locus of each multiplex.
  • the method of this invention comprises the steps of (a) obtaining at least one DNA sample to be analyzed, wherein the DNA sample has at least thirteen loci which can be co-amplified; (b) co-amplifying the at least thirteen loci of the DNA sample; and (c) detecting the amplified materials in a fashion which reveals the polymorphic nature of the systems employed.
  • the present invention is a method of simultaneously determining the alleles present in a set of loci from one or more DNA samples, comprising the steps of: (a) obtaining at least one DNA sample to be analyzed;
  • At least four of the at least thirteen short tandem repeat loci are preferably selected from the group of loci consisting of:
  • the set of loci selected in step (b) of the method comprises thirteen CODIS STR loci (i.e., D3S1358, D5S818, D7S820, D8S1 179, D13S317, D1 6S539, D1 8S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 ) which can be co- amplified and analyzed by themselves, or with additional loci using methods of the present invention.
  • thirteen CODIS STR loci i.e., D3S1358, D5S818, D7S820, D8S1 179, D13S317, D1 6S539, D1 8S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31
  • this invention is a kit for simultaneously analyzing a set of loci of genomic DNA, comprising oligonucleotide primers for co- amplifying a set of loci of the genomic DNA to be analyzed, wherein the set of loci comprises at least thirteen short tandem repeat loci which can be co- amplified in the same multiplex reaction, and wherein the primers are in one or more containers.
  • the kit comprises oligonucleotide primer pairs for co-amplifying a set of at least thirteen loci of human genomic DNA, the set of loci comprising D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 ,
  • the invention is primer sequences and primer pairs for amplifying specific loci of human DNA.
  • Use of the primers and primer pairs of this invention for multiplex analysis of human DNA is demonstrated herein, below.
  • the primers of this invention are suitable for use in the method of this invention, wherein they can be used in labeled form, as noted below, to assist the evaluation step of the method.
  • the approaches specified in the present invention produce savings of time, labor, and materials in the analysis of loci contained within the multiplexes.
  • the method of the present invention allows thirteen or more, even as many as sixteen or more, loci to be co-amplified in one tube using a single amplification reaction, instead of amplifying each locus independently in separate tubes or in smaller groups of loci.
  • the present invention has specific use in the field of forensic analysis, paternity determination, monitoring of bone marrow transplantation, linkage mapping, and detection of genetic diseases and cancers.
  • thirteen methods of the present invention significantly increase the certainty with which one can match DNA prepared from different samples from the same individual.
  • the need to match or distinguish accurately between samples containing very small amounts of DNA is particularly acute in forensics applications, where many convictions (and acquittals) turn on DNA typing analysis.
  • Figure 1 A is a plot of the output of three-color fluorescent detection of the products of simultaneous amplification of the loci D3S1 358, D5S81 8, D7S820, D8S1 179, D13S317, D1 6S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 of a sample of human genomic DNA, as detected with the ABI PRISM 00 310 Genetic Analyzer in
  • Figure 1 B is a plot of the output of three-color fluorescent detection of a control sample processed the same way as Figure 1 A, with no genomic DNA in the amplification reaction.
  • Figure 2A is a plot of the output of three-color fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , G475, S1 59, and Amelogenin of a sample of human genomic DNA, as detected with the ABI PRISM * 310 Genetic Analyzer in Example 2.
  • Figure 2B is a plot of the output of three-color fluorescent detection of a control sample processed the same way as Figure 2A, with no genomic DNA substrate in the amplification reaction.
  • Figure 3A is a plot of the output of three-color fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S818,
  • Figure 3B is a plot of the output of three-color fluorescent detection of a control sample processed the same way as Figure 3A, with no genomic DNA substrate in the amplification reaction.
  • Figures 4A and 4B are laser printed images of the results of fluorescent detection of the products of simultaneous amplification of the loci D3S1358,
  • Figures 5A and 5B are laser printed images of the results of fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S81 8, D7S820, D8S1 1 79, D1 3S31 7, D1 6S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , G475, S1 59, and Amelogenin as detected using the fluorescein channel ( Figure 5A) and carboxy-tetramethylrhodamine channel ( Figure 5B) of a Hitachi FMBIO ⁇ II Fluorescent Scanner, as described in Example 5.
  • Figure 6A and 6B are laser printed images of the results of fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S818, D7S820, D8S1 179, D1 3S317, D16S539, D18S51 , D21 S1 1 ,
  • Allelic ladder a standard size marker consisting of amplified alleles from the locus.
  • Allele a genetic variation associated with a segment of DNA, i.e., one of two or more alternate forms of a DNA sequence occupying the same locus.
  • Biochemical nomenclature standard biochemical nomenclature is used herein in which the nucleotide bases are designated as adenine (A); thymine (T); guanine (G); and cytosine (C). Corresponding nucleotides are, for example, deoxyguanosine-5'-triphosphate (dGTP).
  • DNA polymorphism the condition in which two or more different nucleotide sequences in a DNA sequence coexist in the same interbreeding population.
  • Locus or “genetic locus”: a specific position on a chromosome. Alleles of a locus are located at identical sites on homologous chromosomes. "Locus-specific primer”: a primer that specifically hybridizes with a portion of the stated locus or its complementary strand, at least for one allele of the locus, and does not hybridize efficiently with other DNA sequences under the conditions used in the amplification method.
  • Pentanucleotide tandem repeat a subclass of the STR polymorphisms defined below. Unless specified otherwise, the term “pentanucleotide tandem repeat” encompasses perfect STRs wherein the repeat unit is a five base sequence, and imperfect STRs wherein at least one repeat unit is a five base repeat.
  • Polymerase chain reaction or “PCR”: a technique in which cycles of denaturation, annealing with primer, and extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence by approximately 10 6 times or more.
  • the polymerase chain reaction process for amplifying nucleic acid is covered by U. S. Patent Nos. 4,683,195 and 4,683,202, which are incorporated herein by reference for a description of the process.
  • STR loci Polymorphic short tandem repeat loci, defined below, in which the number of repetitive sequence elements (and net length of sequence) in a particular region of genomic DNA varies from allele to allele, and from individual to individual.
  • Polymorphism information content or "PIC”: a measure of the amount of polymorphism present at a locus (Botstein et al., 1980). PIC values range from 0 to 1 .0, with higher values indicating greater degrees of polymorphism.
  • This measure generally displays smaller values than the other commonly used measure, i.e., heterozygosity.
  • markers that are highly informative heterozygosities exceeding about 70%
  • the difference between heterozygosity and PIC is slight.
  • Primer a single-stranded oligonucleotide or DNA fragment which hybridizes with a DNA strand of a locus in such a manner that the 3' terminus of the primer may act as a site of polymerization using a DNA polymerase enzyme.
  • Primer pair two primers including, primer 1 that hybridizes to a single strand at one end of the DNA sequence to be amplified and primer 2 that hybridizes with the other end on the complementary strand of the DNA sequence to be amplified.
  • Primer site the area of the target DNA to which a primer hybridizes.
  • STR loci regions of genomic DNA which contain short, repetitive sequence elements of 3 to 7 base pairs in length.
  • the term STR also encompasses a region of genomic DNA wherein more than a single three to seven base sequence is repeated in tandem or with intervening bases, provided that at least one of the sequences is repeated at least two times in tandem. Each sequence repeated at least once within an STR is referred to herein as a "repeat unit.”
  • the sequences of the STR loci analyzed using the materials and methods of the present invention can be divided into two general categories, perfect and imperfect.
  • the term "perfect” STR refers to a region of double-stranded DNA containing a single three to seven base repeat unit repeated in tandem at least two times, e.g. (AAAAT) 2 .
  • the term "imperfect” STR refers to a region of DNA containing at least two tandem repeats of a perfect repeat unit and at least one repeat of an imperfect repeat unit, wherein the imperfect repeat unit consists of a DNA sequence which could result from one, two, three, or four base insertions, deletions, or substitutions in the sequence of the perfect repeat unit, e.g.
  • Every imperfect STR sequence contains at least one perfect STR sequence. Specifically, every STR sequence, whether perfect or imperfect, includes at least one repeat unit sequence appearing at least two times in tandem, a repeat unit sequence which can be represented by formula (I):
  • a w G y C 2 (A w G y C 2 ) n (I) wherein A, G, T, and C represent the nucleotides which can be in any order; w, x, y and z represent the number of each nucleotide in the sequence and range from 0 to 7 with the sum of w + x + y + z ranging between 3 and 7; and n represents the number of times the sequence is tandemly repeated and is at least 2.
  • the method of the present invention contemplates selecting an appropriate set of loci, primers, and amplification protocols to generate amplified alleles from multiple co-amplified loci which preferably do not overlap in size or, more preferably, which are labeled in a way which enables one to differentiate between the alleles from different loci which overlap in size.
  • this method contemplates the selection of short tandem repeat loci which are compatible for use with a single amplification protocol. The specific combinations of loci described herein are unique in this application.
  • Combinations of loci may be rejected for either of the above two reasons, or because, in combination, one or more of the loci do not produce adequate product yield, or fragments which do not represent authentic alleles are produced in this reaction.
  • Successful combinations in addition to those disclosed herein can be generated by trial and error of locus combinations, by selection of primer pair sequences, and by adjustment of primer concentrations to identify an equilibrium in which all included loci may be amplified.
  • any one of a number of different techniques can be used to select a set of loci for use in the present invention.
  • One preferred technique for developing useful sets of loci for use in this method of analysis is described below.
  • D1 3S317, and D5S818 was used to generate derivative multiplexes of:
  • HUMCSF1PO HUMTPOX
  • HUMTH01 D16S539
  • D7S820 D13S317
  • D5S818 HUMCSF1PO
  • HUMTPOX HUMTH01, HUMvWFA31, D16S539
  • loci selected for multiplex analysis share the following characteristics: (1) they produce sufficient amplification product to allow evaluation; (2) they generate few if any artifacts due to the addition (or lack of addition) of a base to the amplified alleles during the multiplex amplification step; (3) they generate few, if any, artifacts due to premature termination of amplification reactions by a polymerase; and (4) they produce little or no "trailing" bands of smaller molecular weight from consecutive single base deletions below a given authentic amplified allele. See, e.g., Schumm et al., Fourth International
  • the same technique used to identify the set of at least three loci, described above, can be applied to select thirteen or more loci of human genomic DNA or multiplex analysis, according to a preferred embodiment of the method of analysis of the present invention.
  • Any set of loci identified as described above is suitable for multiplex analysis in accordance with the present invention, provided the set of loci comprises at least thirteen STR loci. More preferably, at least four of the at least thirteen STR loci analyzed according to the present invention are selected from the group of loci consisting of: D3S1 539, D4S2368, D5S818, D7S820, D9S930, D10S1239,
  • the set of loci analyzed according to the present invention includes all thirteen CODIS loci, i.e.
  • At least one of the loci selected for co-amplification in the present multiplex reaction is preferably an STR locus with a repeat unit of five to seven bases or base pairs in length, more preferably an STR locus with a pentanucleotide repeat.
  • loci with such intermediate length repeats can be amplified with minimal incidence of artifacts, e.g. due to repeat slippage.
  • the terms "G475", "C221 ", and "S1 59", as used herein, refer to names assigned to pentanucleotide repeat loci identified, as described in U.S. Pat. App. Serial No. 09/018,584, incorporated by reference above. Each name corresponds to a clone from which each pentanucleotide locus was identified.
  • the sequence of the G475 clone, described therein as SEQ ID NO:34, is identified herein as SEQ ID NO: 108.
  • the sequence of the C221 clone, described therein as SEQ ID NO:2, is identified herein as SEQ ID NO: 109.
  • the sequence of the S1 59 clone, described therein as SEQ ID NO: 26, is identified herein as SEQ ID NO: 1 10.
  • Individual primers and primer pairs identified for use in amplifying G475, C221 , and SI 59 therein can also be used to amplify the same loci in the sets of at least thirteen loci co-amplified and analyzed according to the present invention.
  • the set of loci selected for co-amplification and analysis according to the invention preferably further comprises at least one locus in addition to the at least thirteen STR loci.
  • the additional locus preferably includes a sequence polymorphism, or another feature which identifies a particular characteristic which separates the DNA of an individual from the DNA of other individuals in the population.
  • the additional locus more preferably is a locus which identifies the gender of the source of the DNA sample analyzed. When the DNA sample is human genomic DNA, a gender identifying locus such as the
  • Amelogenin locus is preferably selected for co-amplification and analysis according to the present method.
  • the Amelogenin locus is identified by GenBank as HUMAMELY (when used to identify a locus on the Y chromosome contained in male DNA) or as HUMAMELX (when used to identify a locus on the X chromosome in male or female DNA).
  • Amelogenin locus is co-amplified in the same multiplex amplification reaction as the set of at least thirteen short tandem repeat loci, the sequence of at least one of the primers used to amplify this particular locus in the multiplex amplification reaction preferably has a sequence selected from: SEQ ID NO:86, SEQ ID NO: 105, and SEQ ID NO:87.
  • primers suitable for co-amplifying each locus in the set Care should be used in selecting the sequence of primers used in the multiplex reaction. Inappropriate selection of primers can produce several undesirable effects such as lack of amplification, amplification at multiple sites, primer dimer formation, undesirable interaction of primer sequences from different loci, production of alleles from one locus which overlap with alleles from another, or the need for amplification conditions or protocols for the different loci which are incompatible in a multiplex. Primers used in the present method or included in the present kits of the invention are preferably selected according to the following selection process.
  • Primers are preferably developed and selected for use in the multiplex systems of the invention by employing a re-iterative process of selecting primer sequences, mixing the primers for co-amplification of the selected loci, co-amplifying the loci, then separating and detecting the amplified products. Initially, this process often produces the amplified alleles in an imbalanced fashion (i.e., higher product yield for some loci than for others) and may also generate amplification products which do not represent the alleles themselves. These extra fragments may result from any number of causes described above.
  • individual primers from the total set are used with primers from the same or other loci to identify which primers contribute to the amplification of the extra fragments. Once two primers which generate one or more of the fragments are identified, one or both contributors are modified and retested, either in a pair alone or in the multiplex system (or a subset of the multiplex system). This process is repeated until evaluation of the products yields amplified alleles with no or an acceptable level of extra fragments in the multiplex system.
  • primer concentration may be performed either before or after selection of the final primer sequences, but is preferably performed after that selection. Generally, increasing primer concentration for any particular locus increases the amount of product generated for that locus. However, this is also a re-iterative process because increasing yield for one locus may decrease it for one or more other loci. Furthermore, primers may interact directly affecting yield of the other loci.
  • Linear increases in primer concentration do not necessarily produce linear increases in product yield for the corresponding locus.
  • Locus to locus balance is also affected by a number of parameters of the amplification protocol such as the amount of template used, the number of cycles of amplification, the annealing temperature of the thermal cycling protocol, and the inclusion or exclusion of an extra extension step at the end of the cycling process. Only even balance across all alleles and loci is generally not achieved.
  • the process of multiplex system development may also be a re-iterative process in another sense described, above. That is, it is possible, first, to develop a multiplex system for a small number of loci, this system being free or nearly free of extra fragments from amplification. Primers of this system may be combined with primers for one or more additional loci. This expanded primer combination may or may not produce extra fragments from amplification. In turn, new primers may be introduced and evaluated.
  • One or more of the re-iterative selection processes described above are repeated until a complete set of primers is identified which can be used to co- amplify the at least thirteen loci selected for co-amplification as described above. It is understood that many different sets of primers may be developed to amplify a particular set of loci.
  • primers used in the present method can be conducted using any standard procedure for oligonucleotide synthesis known to those skilled in the art.
  • At least one primer for each locus is preferably covalently attached to a dye label, as described in Section F, below.
  • Table 1 below, provides a list sequences of primers which have been determined to be suitable for use in amplifying the corresponding polymorphic STR loci listed therein.
  • At least one primer listed in Table 1 is preferably used to amplify at least one of the loci selected for co-amplification and analysis as described above. It is understood that other primers could be identified which are suitable for simultaneous amplification of the loci listed below.
  • Samples of genomic DNA can be prepared for use in the method of this invention using any method of DNA preparation which is compatible with the amplification of DNA. Many such methods are known by those skilled in the art. Examples include, but are not limited to DNA purification by phenol extraction (Sambrook, J., et al. (1 989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York., pp. 9.14-9.1 9), and partial purification by salt precipitation (Miller, S. et al. (1988) Nucl. Acids Res.
  • the DNA is preferably prepared from tissue, selected from the group consisting of blood, semen, vaginal cells, hair, saliva, urine, bone, buccal samples, amniotic fluid containing placental cells or fetal cells, chorionic villus, and mixtures of any of the tissues listed above.
  • DNA concentrations can be measured prior to use in the method of the present invention, using any standard method of DNA quantification known to those skilled in the art.
  • the DNA concentration is preferably determined by spectrophotometric measurement as described by Sambrook, J., et al. (1 989), supra, Appendix E.5, or fluorometrically using a measurement technique such as that described by Brunk C. F., et al. (1979), Anal Biochem 92: 497-500.
  • the DNA concentration is more preferably measured by comparison of the amount of hybridization of DNA standards with a human-specific probe such as that described by Waye, J.S., et al.
  • the targeted loci can be co-amplified in the multiplex amplification step of the present method.
  • Any one of a number of different amplification methods can be used to amplify the loci, including, but not limited to, polymerase chain reaction (PCR) (Saiki, R. K., et al. (1985), Science 230: 1350-1 354), transcription based amplification (Kwoh, D. Y., and Kwoh, T. J. (1990), American Biotechnology Laboratory, October, 1990) and strand displacement amplification (SDA) (Walker, G. T., et al. (1992) Proc. Natl. Acad. Sci., U.S.A. 89: 392-396).
  • PCR polymerase chain reaction
  • SDA strand displacement amplification
  • the DNA sample is subjected to PCR amplification using primer pairs specific to each locus in the set.
  • primer pairs specific to each locus in the set.
  • At least one primer for each locus is preferably covalently attached to a dye label, more preferably a fluorescent dye label.
  • the primers and dyes attached thereto are preferably selected for the multiplex amplification reaction, such that alleles amplified using primers for each locus labeled with one color do not overlap the alleles of the other loci in the set co-amplified therein using primers labeled with the same color, when the alleles are separated, preferably, by gel or capillary electrophoresis.
  • At least one primer for each locus co-amplified in the multiplex reaction is labeled with a fluorescent label prior to use in the reaction.
  • Fluorescent labels suitable for attachment to primers for use in the present invention are commercially available. See, e.g. fluorescein and carboxy- tetramethylrhodamine labels and their chemical derivatives from PE Biosystems and Molecular Probes.
  • at least three different labels are used to label the different primers used in the multiplex amplification reaction.
  • the primers used to prepare the size marker are preferably labeled with a different label from the primers used to amplify the loci of interest in the reaction.
  • locus-specific primers used in the Examples include a number of nucleotides which, under the conditions used in the hybridization, are sufficient to hybridize with an allele of the locus to be amplified and to be essentially free from amplification of alleles of other loci.
  • U.S. Patent 5,192,659 to Simons the teaching of which is incorporated herein by reference for a more detailed description of locus-specific primers.
  • the evaluation step of this method can be accomplished by any one of a number of different means, the most preferred of which are described below.
  • Electrophoresis is preferably used to separate the products of the multiplex amplification reaction, more preferably capillary electrophoresis (see, e.g., Buel, Eric et al. (1998), Journal of Forensic Sciences; 43:(1 ) pp. 164- 1 70) or denaturing polyacrylamide gel electrophoresis (see, e.g., Sambrook, J. et al. (1989) In Molecular Cloning— A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, pp. 1 3.45-1 3.57). Gel preparation and electrophoresis procedures and conditions for suitable for use in the evaluating step of the method of this invention are illustrated in the Examples, below. Separation of DNA fragments in a denaturing polyacrylamide gel and in capillary electrophoresis occurs based primarily on fragment size.
  • the alleles and any other DNA in the gel or capillary can then be visualized and analyzed.
  • Visualization of the DNA in the gel can be accomplished using any one of a number of prior art techniques, including silver staining or reporters such as radioisotopes, fluorescers, chemiluminescers and enzymes in combination with detectable substrates.
  • the preferred method for detection of multiplexes containing thirteen or more loci is fluorescence (see, e.g., Schumm, J. W. et al. in Proceedings from the Eighth International Symposium on Human Identification, (pub. 1998 by Promega Corporation), pp.
  • the alleles present in the DNA sample are preferably determined by comparison to a size standard such as a DNA marker or a locus-specific allelic ladder to determine the alleles present at each locus within the sample.
  • a size standard such as a DNA marker or a locus-specific allelic ladder to determine the alleles present at each locus within the sample.
  • the most preferred size marker for evaluation of a multiplex amplification containing two or more polymorphic STR loci consists of a combination of allelic ladders for each of the loci being evaluated. See, e.g., Puers, Christoph et al., (1 993) Am J. Hum Genet. 53:953-958, Puers, Christoph, et al. (1994) Genomics 23:260-264. See also, U.S. Pat. No's 5,599,666; 5,674,686; and
  • allelic ladders for individual loci, these may be mixed and loaded for gel electrophoresis at the same time as the loading of amplified samples occurs. Each allelic ladder co-migrates with alleles in the sample from the corresponding locus.
  • the products of the multiplex reactions of the present invention can be evaluated using an internal lane standard, a specialized type of size marker configured to run in the same lane of a polyacrylamide gel or same capillary.
  • the internal lane standard preferably consists of a series of fragments of known length.
  • the internal lane standard more preferably is labeled with a fluorescent dye which is distinguishable from other dyes in the amplification reaction.
  • this standard can also be mixed with amplified sample or allelic ladders and loaded for electrophoresis for comparison of migration in different lanes of gel electrophoresis or different capillaries of capillary electrophoresis. Variation in the migration of the internal lane standard indicates variation in the performance of the separation medium. Quantitation of this difference and correlation with the allelic ladders allows correction in the size determination of alleles in unknown samples.
  • H. Preferred Detection Technique Fluorescent Detection
  • fluorescent detection is used to evaluate the amplified alleles in the mixture produced by the multiplex amplification reaction. Below is a brief summary of how that method of detection preferably is practiced.
  • fluorescent labeled primers preferably suited for use in the present invention include the fluorescein-labeled (FL-), carboxy- tetramethylrhodamine-labeled (TMR-), and 5,6-carboxyrhodamine 6G-labeled (R6G) primers, such as are illustrated in the Examples, below. Separation of the amplified fragments produced using such labeled primers is achieved preferably by slab gel electrophoresis or capillary electrophoresis.
  • the resulting separated fragments can be analyzed using fluorescence detection equipment such as an ABI PRISM * 310 Genetic Analyzer, an ABI PRISM * 377 DNA Sequencer (Applied Biosystems Division, Perkin Elmer, Foster City, CA), or a Hitachi FMBIO * II Fluorescent Scanner (Hitachi Software Engineering America, Ltd. South San Francisco, CA).
  • fluorescence detection equipment such as an ABI PRISM * 310 Genetic Analyzer, an ABI PRISM * 377 DNA Sequencer (Applied Biosystems Division, Perkin Elmer, Foster City, CA), or a Hitachi FMBIO * II Fluorescent Scanner (Hitachi Software Engineering America, Ltd. South San Francisco, CA).
  • the method of this invention is most preferably practiced using fluorescent detection as the detection step.
  • one or both of each pair of primers used in the multiplex amplification reaction has a fluorescent label attached thereto, and as a result, the amplified alleles produced from the amplification reaction are fluorescently labeled.
  • the amplified alleles are subsequently separated by capillary electrophoresis and the separated alleles visualized and analyzed using a fluorescent image analyzer. Fluorescent detection is preferred over radioactive methods of labeling and detection, because it does not require the use of radioactive materials, and all the regulatory and safety problems which accompany the use of such materials.
  • Fluorescent detection employing labeled primers is also preferred over other non-radioactive methods of detection, such as silver staining, because fluorescent methods of detection generally reveal fewer amplification artifacts than silver staining. The smaller number of artifacts are due, in part, to the fact that only amplified strands of DNA with labels attached are detected in fluorescent detection, while both strands of every amplified allele of DNA produced from the multiplex amplification reaction is stained and detected using the silver staining method of detection.
  • kits that utilize the process described above.
  • a basic kit comprises a container having one or more locus-specific primers. Instructions for use optionally may be included.
  • kit components may include an allelic ladder directed to each of the specified loci, a sufficient quantity of enzyme for amplification, amplification buffer to facilitate the amplification, loading solution for preparation of the amplified material for electrophoresis, genomic DNA as a template control, a size marker to insure that materials migrate as anticipated in the separation medium, and a protocol and manual to educate the user and to limit error in use.
  • the amounts of the various reagents in the kits also can be varied depending upon a number of factors, such as the optimum sensitivity of the process. It is within the scope of this invention to provide test kits for use in manual applications or test kits for use with automated detectors or analyzers.
  • the human genomic DNA samples assayed in the Example below were prepared from blood or tissue culture cells, using a standard procedure described by Miller and Dykes in (Miller, S. et al. ( 1 988) Nucl. Acids Res. 1 6: 1 21 5).
  • the isolation and quantification methods described therein are generally known to those skilled in the art and are preferred, but not required, for application of the invention.
  • Each Example below is an example of the use of the method of this invention, to determine simultaneously the alleles present in at least thirteen loci from one or more DNA samples of human genomic DNA.
  • Each set of loci co-amplified below includes the thirteen short tandem repeat loci identified for use in the CODIS system (i.e., D3S1358, HUMTH01 , D21 S1 1 , D18S51 , HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D1 3S317, D7S820, D16S539, and HUMCSF1 PO).
  • loci co-amplified below also include one or more additional short tandem repeat loci, such as loci with pentanucleotide repeats (e.g., G475, S1 59, or C221 ), and a non-STR locus, Amelogenin.
  • additional short tandem repeat loci such as loci with pentanucleotide repeats (e.g., G475, S1 59, or C221 ), and a non-STR locus, Amelogenin.
  • Table 2 summarizes which set of loci was co-amplified in the multiplex amplification reaction described in each Example below. The table also indicates which primer pair was used to amplify each such locus in each such multiplex reaction. One primer of each primer pair listed on Table 2 was fluorescently labeled prior to being used in the multiplex amplification reaction. In some cases, a different label was used to label primers to different loci, such that the alleles produced using the different primers could be distinguished from one another when detected with a laser-activated fluorescence detection device.
  • fluorescent labels were used in the Examples below, described as “FL” to indicate fluorescein-labeled, "TMR” to indicate carboxy- tetramethylrhodamine-labeled, and "R6G” to indicate 5,6-carboxyrhodamine 6G in Table 2, below.
  • Table 2 also indicates which primer of each pair of primers used in the multiplex amplification reaction was so labeled in each Example (e.g., "FL-69” means the primer with SEQ ID NO:69 was labeled at its 5' end with fluorescein prior to being used in the multiplex amplification reaction).
  • a DNA template was amplified simultaneously at the individual loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S81 8, D7S820, D13S317, D16S539, and HUMCSF1 PO in a single reaction vessel.
  • the PCR amplification was performed in 25 ⁇ l of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH)
  • Amplified products were separated using an ABI PRISM * 310 Genetic Analyzer. DNA samples were mixed with 24 ⁇ l of a loading solution
  • Conditions for the electrophoresis were a 5 second injection, injection kV was 15.0, run kV was 1 5.0, run temperature was 60°C, run time was 28 minutes and virtual filter A was used.
  • Figure 1 A is a printout of results of scanning the amplified fragments of each locus separated and detected with the ABI PRISM * 310 Genetic
  • Figure 1 A shows amplification products of a DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, and HUMCSF1 PO. Peaks shown in Panel A are labeled with fluorescein, peaks shown in Panel B are labeled with carboxy-tetramethylrhodamine, and peaks shown in Panel C are labeled with 5,6 carboxyrhodamine 6G.
  • Figure 1 B is a printout of the results of scanning a sample prepared in the same way as the sample scanned in Figure 1 A, except that no DNA template was used in the amplification reaction. Peaks in this figure are background products resulting from dye conjugation and purification procedures and from undefined causes.
  • a DNA template was amplified simultaneously at the individual loci D3S1 358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S81 8, D7S820,
  • System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 12 min., then 10 cycles of 94°C for 30 sec, ramp for 68 sec. to 58°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 20 cycles of 90°C for 30 sec, ramp 60 sec. to 58°C, hold for 30 sec, ramp for 50 sec, to 70°C, hold for 45 sec, followed by 1 cycle of 60°C for 30 min.
  • Amplified products were separated using an ABI PRISM * 310 Genetic Analyzer. DNA samples were mixed with 24 ⁇ l of a loading solution
  • Conditions for the electrophoresis were a 5 second injection, injection kV was 1 5.0, run kV was 1 5.0, run temperature was 60°C, run time was 28 minutes and virtual filter A was used.
  • Figure 2A is a printout of results of scanning the amplified fragments of each locus separated and detected with the ABI PRISM * 310 Genetic
  • Figure 2A shows amplification products of a DNA sample simultaneously co-amplified for the loci D3S1 358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D1 3S317, D16S539, HUMCSF1 PO, and S159. Peaks shown in Panel A are labeled with fluorescein, peaks shown in
  • Panel B are labeled with carboxy-tetramethylrhodamine, and peaks shown in Panel C are labeled with 5,6 carboxyrhodamine 6G.
  • Figure 2B is a printout of the results of scanning a sample prepared in the same way as the sample scanned in Figure 2A, except that no DNA template was used in the amplification reaction. Peaks in this figure are background products resulting from dye conjugation and purification procedures and from undefined causes.
  • a DNA template was amplified as in Example 2.
  • Amplified products were separated using an ABI PRISM * 377 DNA Sequencer. This was carried out using a 0.2mm thick, 5% Long RangerTM Acrylamide (FMC BioProducts, Rockland, ME), 7M urea gel.
  • DNA samples were mixed with 1 .5 ⁇ l of a loading solution (88.25% formamide, 4.1 mM EDTA, 1 5mg/ml
  • FIG. 3A is a printout of results of scanning the amplified fragments of each locus separated and detected with the ABI PRISM * 377 DNA Sequencer, as described above.
  • Figure 3A shows amplification products of a DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO, and
  • Peaks shown in Panel A are labeled with fluorescein, peaks shown in Panel B are labeled with carboxy-tetramethylrhodamine, and peaks shown in Panel C are labeled with 5,6 carboxyrhodamine 6G.
  • Figure 3B is a printout of the results of scanning a sample prepared in the same way as the sample scanned in Figure 3A, except that no DNA template was used in the amplification reaction. Peaks in this figure are background products resulting from dye conjugation and purification procedures and from undefined causes.
  • Amplification of each locus combination included 5ng template in a single reaction vessel containing 25 ⁇ l of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 %
  • Triton X-100 1 .5mM MgCI 2 160//g/ml BSA and 200 yM each of dATP, dCTP, dGTP and dTTP).
  • a GeneAmp * PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 1 2 min., then
  • each template was amplified using 2.5 U of AmpliTaq Gold TM DNA Polymerase and primers for each locus used in the concentrations described above for the loci D3S1 358, HUMTH01 , D21 S1 1 ,
  • each template was amplified using 1 .5 U of AmpliTaq GoldTM DNA Polymerase and primers for each locus used in the concentrations described above for the loci D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and
  • Amplification products were separated by electrophoresis through a 0.4 mm thick 4% denaturing polyacrylamide gel (19:1 ratio of acrylamide to bis- acrylamide) which contained 7 M urea (Sambrook et al., (1989)), and which was chemically cross-linked to 2 glass plates (Kobayashi, Y. (1988), BRL
  • DNA samples were mixed with 3.5 ⁇ l of a loading solution (10mM NaOH, 95% formamide, 0.05% bromophenol blue) and 0.5 ⁇ l of an internal lane size standard, denatured at 95°C for 2 min., and chilled on ice prior to loading.
  • the separated products were visualized by detection of the fluorescent signals using the Hitachi FMIBO * II fluorescent scanner (Hitachi Software Engineering America, Ltd. South San Francisco, CA). Band pass filters at 505 nm and 585 nm, respectively, were used for the detection of fluorescein-labeled loci and carboxy-tetramethylrhodamine-labeled loci, respectively.
  • FIG. 4A shows the results from the 505 nm scan (Fluorescein channel) and Figure 4B shows the results from the 585 nm scan (carboxy-tetramethylrhodamine channel) of the same lanes of the polyacrylamide gel.
  • lane 1 shows the results of the DNA sample which has been simultaneously co-amplified for the loci
  • Lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA.
  • Lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D1 3S317, D7S820, D1 6S539, HUMCSF1 PO, and
  • Lane 3 shows the results of the DNA sample simultaneously co- amplified for the loci D5S818, D13S317, D7S820, D16S539, HUMCSF1 PO, and S1 59.
  • HUMTH01 D21 S1 1 . D18S51 . G475. Amelogenin. HUMvWFA31 .
  • HUMvWFA31 D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and S159.
  • Amplification of each locus combination included 5ng template in a single reaction vessel containing 25 ⁇ l of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 %
  • Triton X-100 1 .5mM MgCI 2, 160 ⁇ g/ml BSA and 200 ⁇ M each of dATP, dCTP, dGTP and dTTP).
  • a GeneAmp * PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 12 min., then
  • each template was amplified using 2.5 U of AmpliTaq GoldTM DNA Polymerase and primers for each locus used in the concentrations described above for the loci D3S1358, HUMTH01 , D21 S1 1 ,
  • Figure 5A and 5B display the fragments resulting from each amplification reaction.
  • Figure 5A shows the results from the 505 nm scan (Fluorescein channel) and
  • Figure 5B shows the results from the 585 nm scan (carboxy-tetramethylrhodamine channel) of the same lanes of the polyacrylamide gel.
  • lane 1 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 ,
  • D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA and lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D13S317, D7S820, D16S539, HUMCSF1 PO, and
  • Amplification of each locus combination included 10ng template in a single reaction vessel containing 25 ⁇ l of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 % Triton X-100, 1 .5mM MgCI 2> 160 ⁇ g/ml BSA and 200 ⁇ M each of dATP, dCTP, dGTP and dTTP).
  • a GeneAmp * PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 1 2 min., then 10 cycles of 94°C for 30 sec, ramp for 68 sec. to 60°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 20 cycles of 90°C for
  • each template was amplified using 2.5 U of AmpliTaq Gold TM DNA Polymerase and primers for each locus used in the concentrations described above for the loci D3S1358, HUMTH01 , D21 S1 1 , D1 8S51 , S1 59, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA.
  • each template was amplified using 1 .5 U of AmpliTaq Gold TM DNA Polymerase and primers for each locus used in the concentrations described above for the loci D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and C221 .
  • Figure 6A shows the results from the 505 nm scan (Fluorescein channel) and Figure 6B shows the results from the 585 nm scan (carboxy-tetramethylrhodamine channel) of the same lanes of the polyacrylamide gel.
  • lane 1 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , S159, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA.
  • Lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1 358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX,
  • Lane 3 shows the results of the DNA sample simultaneously co- amplified for the loci D5S818, D13S317, D7S820, D16S539, HUMCSF1 PO, and C221 .

Abstract

Methods and materials are disclosed for use in simultaneously amplifying at least thirteen loci of genomic DNA in a single multiplex reaction, as are methods and materials for use in the analysis of the products of such reactions. Included in the present invention are materials and methods for the simultaneous amplification of at least thirteen short tandem repeat loci, including specific materials and methods for the analysis of thirteen such loci specifically selected by the United States Federal Bureau of Investigation as core loci for use in the Combined DNA Index System (CODIS) database.

Description

MULTIPLEX AMPLIFICATION OF SHORT TANDEM REPEAT LOCI
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of United States patent application serial number 08/632,575, filed April 1 5, 1996, now U.S. patent number 5,843,660, issued December 1 , 1998, which is a continuation-in-part of United States patent application serial number 08/316,544, filed September 30, 1994. The entire disclosure of those applications is incorporated by reference herein.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.
FIELD OF THE INVENTION
The present invention is generally directed to the detection of genetic markers in a genomic system. The present invention is more specifically directed to the simultaneous amplification of multiple distinct polymorphic genetic loci using the polymerase chain reaction or other amplification systems to determine, in one reaction, the alleles of each locus contained within the multiplex system.
BACKGROUND OF THE INVENTION DNA typing is commonly used to identify the parentage of human children, and to confirm the lineage of horses, dogs, other animals, and agricultural crops. DNA typing is also commonly employed to identify the source of blood, saliva, semen, and other tissue found at a crime scenes or other sites requiring identification of human remains. DNA typing is also employed in clinical settings to determine success or failure of bone marrow transplantation and presence of particular cancerous tissues. DNA typing involves the analysis of alleles of genomic DNA with characteristics of interest, commonly referred to as "markers". Most typing methods in use today are specifically designed to detect and analyze differences in the length and/or sequence of one or more regions of DNA markers known to appear in at least two different forms in a population. Such length and/or sequence variation is referred to as "polymorphism." Any region (i.e. "locus") of DNA in which such a variation occurs is referred to as a "polymorphic locus." The methods and materials of the present invention are designed for use in the detection of multiple loci of DNA, some or all of which are polymorphic loci.
Genetic markers which are sufficiently polymorphic with respect to length or sequence have long been sought for use in identity applications, such as paternity testing and identification of tissue samples collected for forensic analysis. The discovery and development of such markers and methods for analyzing such markers have gone through several phases of development over the last several years.
The first identified DNA variant markers were simple base substitutions, i.e. simple sequence polymorphisms, which were most often detected by Southern hybridization assays. For examples of references describing the identification of such markers, designed to be used to analyze restriction endonuclease-digested DNA with radioactive probes, see: Southern, E. M. (1975), J. Mol. Biol. 98(3):503-507; Schumm, et al. (1988), American Journal of Hυman Genetics 42:143-1 59; and Wyman, A. and White, R. (1980) Proc. Natl. Acad. Sci, U.S.A. 77:6754-6758.
The next generation of markers were size variants, i.e. length polymorphisms, specifically "variable number of tandem repeat" (VNTR) markers (Nakamura Y., et al. (1987), Science 235: 1616-1622; and U.S. Pat. No. 4,963,663 issued to White et al. (1990); U.S. Pat. No. 5,41 1 ,859 continuation of 4,963,663 issued to White et al. (1995)) and "minisatellite" markers (Jeffreys et al. (1985a), Nature 314:67-73; Jeffreys et al. (1985b) Nature 316:76-79., U.S. Pat. No. 5,175,082 for an invention by Jeffreys). Both VNTR and minisatellite markers, contain regions of nearly identical sequences repeated in tandem fashion. The core repeat sequence is 10 to
70 bases in length, with shorter core repeat sequences referred to as "minisatellite" repeats and longer repeats referred to as VNTRs. Different individuals in a human population contain different numbers of the repeats. The VNTR markers are generally more highly polymorphic than base substitution polymorphisms, sometimes displaying up to forty or more alleles at a single genetic locus. However, the tedious process of restriction enzyme digestion and subsequent Southern hybridization analysis are still required to detect and analyze most such markers.
The next advance involved the joining of the polymerase chain reaction (PCR) (U.S. Pat. No. 4,683,202 by Mullis, K.B.) technology with the analysis of VNTR loci (Kasai, K. et al. (1990) Journal Forensic Science 35(5):1 196-
1200). Amplifiable VNTR loci were discovered, which could be detected without the need for Southern transfer. The amplified products are separated through agarose or polyacrylamide gels and detected by incorporation of radioactivity during the amplification or by post-staining with silver or ethidium bromide. However, PCR can only be used to amplify relatively small
DNA segments reliably, i.e. only reliably amplifying DNA segments under 3,000 bases in length Ponce, M & Micol, L. (1992) NAR 20(3): 623; Decorte R, et al. (1990) DNA Cell Biol. 9(6):461-469). Consequently, very few amplifiable VNTRs have been developed. In recent years, the discovery and development of polymorphic short tandem repeats (STRs) as genetic markers has stimulated progress in the development of linkage maps, the identification and characterization of diseased genes, and the simplification and precision of DNA typing. Specifically, with the discovery and development of polymorphic markers containing dinucleotide repeats (Litt and Luty (1989) Am J. Hum Genet
3(4):599-605; Tautz, D (1989) NAR 17:6463-6471 ; Weber and May (1989) Am J Hum Genet 44:388-396; German Pat. No. DE 38 34 636 C2, inventor Tautz, D; U.S. Pat. No. 5,582,979 filed by Weber, L.), STRs with repeat units of three to four nucleotides (Edwards, A., et al. (1991 ) Am. J. Hum. Genet. 49: 746-756.; Hammond, H.A., et al. (1994) Am. J. Hum. Genet. 55: 175-
189; Fregeau, C.J.; and Fourney, R.M. (1993) BioTechniques 15(1 ): 100- 1 19.; Schumm, J.W. et al. (1994) in The Fourth International Symposium on Human Identification 1993, pp. 177-187 (pub. by Promega Corp., 1994); and U.S. Pat. No. 5,364,759 by Caskey et al.; German Pat. No. DE 38 34 636 C2 by Tautz, D.) and STRs with repeat units of five to seven bases (See, e.g. Edwards et al. (1991 ) Nucleic Acids Res. 19:4791 ; Chen et al. (1993)
Genomics 1 5(3): 621 -5; Harada et al. (1 994) Am. J. Hum. Genet. 55: 175- 189; Comings et al. (1995), Genomics 29(2):390-6; and Utah Marker Development Group (1995), Am. J. Genet. 57:619-628; and Jurka and Pethiyagoda (1995) J. Mol. Evol. 40: 1 20-126)), many of the deficiencies of previous methods have been overcome. STR markers are generally shorter than VNTR markers, making them better substrates for amplification than most VNTR markers.
STR loci are similar to amplifiable VNTR loci in that the amplified alleles at each such locus may be differentiated based on length variation. Generally speaking STR loci are less polymorphic at each individual locus than VNTR loci. Thus, it is desirable to amplify and detect multiple STR systems in a single amplification reaction and separation to provide information for several loci simultaneously. Systems containing several loci are called multiplex systems and many such systems containing up to 1 1 separate STR loci have been described. See, e.g., Proceedings: American Academy of Forensic
Sciences (Feb. 9-14, 1998), Schumm, James W. et al., p. 53, B88; Id., Gibson, Sandra D. et al., p. 53, B89; Id., Lazaruk, Katherine et al., p. 51 , B83; Sparkes, R. et al., Int J Legal Med (1996) 109:186-194; AmoFOSTR Profiler™ PCR Amplification Kit User's Manual (1997), pub by Perkin-Elmer Corp. i-viii and 1 -1 to 1 -10: AmoFflSTR Profiler Plus™ PCR Amplification Kit
User's Manual (1 997), pub by Perkin-Elmer Corp., i viii and 1 -1 to 1 -10; AmpFCSTR COfiler™ PCR Amplification Kit User Bulletin (1998), pub by Perkin-Elmer Corp. i-iii and 1-1 to 1-10; 9th International Symposium on Human Identification (October 7-10, 1998), pub. by Promega Corp., Staub, Rick W. et al., Poster Abstract 1 5; Id., Willard, Jeanne M. et al., Poster Abstract 73; and Id., Walsh, P. Sean, et al., Speaker Abstract for 8:50am - 9:20am, Thursday, October 8, 1 998.
Amplification protocols with STR loci can be designed to produce small products, generally from 60 to 500 base pairs (bp) in length, and alleles from each locus are often contained within a range of less than 100 bp. This allows simultaneous electrophoretic analysis of several systems on the same gel or capillary electrophoresis by careful design of PCR primers such that all potential amplification products from an individual system do not overlap the range of alleles of other systems. Design of these systems is limited, in part, by the difficulty in separating multiple loci in a single gel or capillary. This occurs because there is spacial compression of fragments of different sizes, especially longer fragments in gels or capillaries, i.e., commonly used means for separation of DNA fragments by those skilled in the art.
The United States Federal Bureau of Investigation ("FBI") has established and maintains a Combined DNA Index System ("CODIS"), a database of DNA typing information. Local, state, and national law enforcement agencies use the CODIS system to match forensic DNA evidence collected at crime scenes with DNA information in the database. CODIS and other national database systems have proven to be an effective tool for such agencies to use in solving violent crimes. (See, e.g. Niezgoda,
Stephen, in Cambridge Healthtech Institute's Second Annual Conference on DNA Forensics: Science. Evidence . and Future Prospects (Nov. 17-18, 1 998), pp. 1 -21 .; Niezgoda, Stephen in Proceedings From The Eighth International Symposium on Human Identification 1997. pub. by Promega Corporation (1 998), pp 48-49; Frazier, Rachel R.E. et al. Id., pp. 56-60;
Niezgoda, S.J. Profiles in DNA 1 (3): 1 2-1 3; Werrett, D.J. and Sparkes, R. in Speaker Abstracts: 9th International Symposium on Human Identification (Oct. 7-10, 1998) pp. 5-6). Until recently, only restriction fragment length polymorphism ("RFLP") data obtained from the analysis of particular VNTR loci was considered a core component in the database. The FBI has recently identified thirteen polymorphic STR loci for inclusion in the CODIS database. The thirteen CODIS STR loci are HUMCSF1 PO, D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D1 8S51 , D21 S1 1 , HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 . (Budowle, Bruce and Moretti, Tamyra in Speaker Abstracts: 9th International Symposium on Human Identification (Oct. 7-10, 1998) pp. 7-8). Both VNTR and STR marker data are currently maintained in the CODIS database. (See, e.g. Niezgoda, Stephen in Second Annual Conference on DNA Forensics. supra). Until the present invention, the number of loci which could be co-amplified in a single reaction, and analyzed thereafter was limited. Specifically, no materials or methods had been developed for use in multiplex amplification of thirteen or more STR loci, much less the thirteen polymorphic STR loci identified for use in the CODIS database.
The materials and methods of the present method are designed for use in multiplex analysis of particular polymorphic loci of DNA of various types, including single-stranded and double-stranded DNA from a variety of different sources. The present invention represents a significant improvement over existing technology, bringing increased power of discrimination, precision, and throughput to DNA profiling for linkage analysis, criminal justice, paternity testing, and other forensic, medical, and genetic identification applications.
SUMMARY OF THE INVENTION It is, therefore, an object of the present invention to provide a method and materials for the simultaneous amplification of sets of loci, which include multiple distinct polymorphic short tandem repeat (STR) loci, in a single multiplex reaction, using PCR or other amplification systems in combination with gel electrophoresis, capillary electrophoresis or other separation and detection methods to analyze and compare the relative lengths of the alleles of each locus amplified in the multiplex reaction. Multiplex analysis of the sets of loci disclosed herein has not been previously described in the prior art. There has also not been any previous description of the sequences for many of the primers disclosed herein below, all of which are shown to be useful in multiplex amplification of the sets of loci disclosed.
It is also an object of the present invention to provide a method, a kit, and primers specific for multiplex amplifications comprising specified loci.
These and other objects are addressed by the present invention which is directed to a method and materials for simultaneously analyzing or determining the alleles present at each individual locus of each multiplex. In general, the method of this invention comprises the steps of (a) obtaining at least one DNA sample to be analyzed, wherein the DNA sample has at least thirteen loci which can be co-amplified; (b) co-amplifying the at least thirteen loci of the DNA sample; and (c) detecting the amplified materials in a fashion which reveals the polymorphic nature of the systems employed.
In one embodiment, the present invention is a method of simultaneously determining the alleles present in a set of loci from one or more DNA samples, comprising the steps of: (a) obtaining at least one DNA sample to be analyzed;
(b) selecting a set of loci of the DNA sample, comprising at least thirteen short tandem repeat loci which can be co-amplified;
(c) co-amplifying the loci in the set in a multiplex amplification reaction, wherein the product of the reaction is a mixture of amplified alleles from each of the co-amplified loci in the set; and
(d) evaluating the amplified alleles in the mixture to determine the alleles present at each of the loci analyzed in the set within the DNA sample.
At least four of the at least thirteen short tandem repeat loci are preferably selected from the group of loci consisting of:
D3S1539, D4S2368, D5S818, D7S820, D9S930, D10S1239, D13S317, D14S118, D14S548, D14S562, D16S490, D16S539, D16S753, D17S1298, D17S1299, D19S253, D20S481, D22S683, HUMCSF1PO, HUMTPOX, HUMTH01, HUMF13A01, HUMBFXIII, HUMLIPOL, HUMvWFA31.
In another embodiment of the invention, the set of loci selected in step (b) of ln another embodiment of the invention, the set of loci selected in step (b) of the method comprises thirteen CODIS STR loci (i.e., D3S1358, D5S818, D7S820, D8S1 179, D13S317, D1 6S539, D1 8S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 ) which can be co- amplified and analyzed by themselves, or with additional loci using methods of the present invention.
In a further aspect, this invention is a kit for simultaneously analyzing a set of loci of genomic DNA, comprising oligonucleotide primers for co- amplifying a set of loci of the genomic DNA to be analyzed, wherein the set of loci comprises at least thirteen short tandem repeat loci which can be co- amplified in the same multiplex reaction, and wherein the primers are in one or more containers. More preferably, the kit comprises oligonucleotide primer pairs for co-amplifying a set of at least thirteen loci of human genomic DNA, the set of loci comprising D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 ,
HUMTPOX, and HUMvWFA31 .
In yet a further aspect, the invention is primer sequences and primer pairs for amplifying specific loci of human DNA. Use of the primers and primer pairs of this invention for multiplex analysis of human DNA is demonstrated herein, below. The primers of this invention are suitable for use in the method of this invention, wherein they can be used in labeled form, as noted below, to assist the evaluation step of the method.
The approaches specified in the present invention produce savings of time, labor, and materials in the analysis of loci contained within the multiplexes. The method of the present invention allows thirteen or more, even as many as sixteen or more, loci to be co-amplified in one tube using a single amplification reaction, instead of amplifying each locus independently in separate tubes or in smaller groups of loci.
The present invention has specific use in the field of forensic analysis, paternity determination, monitoring of bone marrow transplantation, linkage mapping, and detection of genetic diseases and cancers. By allowing thirteen methods of the present invention significantly increase the certainty with which one can match DNA prepared from different samples from the same individual. The need to match or distinguish accurately between samples containing very small amounts of DNA is particularly acute in forensics applications, where many convictions (and acquittals) turn on DNA typing analysis.
Scientists, particularly forensic scientists, have long appreciated the need to analyze multiple polymorphic loci of DNA in order to ensure that a match between two samples of DNA is statistically significant. (Presley, L. A. et al., in The Third International Symposium on Human Identification
1 992. pp. 245-269 (pub. by Promega Corp., 1 993); Bever, R. A., et al., in The Second International Symposium on Human Identification 1991 . pp. 103- 1 28. (pub. by Promega Corp., 1992)) However, until this invention, one could not simultaneously analyze thirteen or more STR loci in a single reaction. To realize the importance of such multiplexing capabilities, it helps to understand some of the mathematics behind DNA typing analysis.
For purposes of illustration, suppose every STR locus has a genotype
(i.e., pattern of two alleles) frequency of one in ten. In other words, suppose that the chance of two randomly selected individuals have a matching type for a single STR is 1 /10. However, if two different STR loci are analyzed, the chance of a random match with both systems is 1 /100. If three STR loci are analyzed, the chances of a random match with each of the three systems is
1 /1 ,000 and so on. Consequently, it is easy to see how increasing the number of STR loci analyzed reduces the likelihood of random matches within the general population, thereby increasing the chance one can accurately identify a suspect's presence at a crime scene by comparing the individual's type with crime scene evidence. Similar reasoning can be used to conclude that the method of this invention also would increase the likelihood of accurately identifying a suspected father in a paternity case, of correctly matching bone marrow tissue, of developing significant results from linkage mapping studies, and of detecting genetic diseases and cancers. Further objects, features, and advantages of the invention will be apparent from the following best mode for carrying out the invention and the illustrative drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 A is a plot of the output of three-color fluorescent detection of the products of simultaneous amplification of the loci D3S1 358, D5S81 8, D7S820, D8S1 179, D13S317, D1 6S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 of a sample of human genomic DNA, as detected with the ABI PRISM00 310 Genetic Analyzer in
Example 1 .
Figure 1 B is a plot of the output of three-color fluorescent detection of a control sample processed the same way as Figure 1 A, with no genomic DNA in the amplification reaction. Figure 2A is a plot of the output of three-color fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , G475, S1 59, and Amelogenin of a sample of human genomic DNA, as detected with the ABI PRISM* 310 Genetic Analyzer in Example 2.
Figure 2B is a plot of the output of three-color fluorescent detection of a control sample processed the same way as Figure 2A, with no genomic DNA substrate in the amplification reaction.
Figure 3A is a plot of the output of three-color fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S818,
D7S820, D8S1 179, D13S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , G475, S1 59, and Amelogenin of a sample of human genomic DNA, as detected with an ABI PRISM" 377 DNA Sequencer in Example 3. Figure 3B is a plot of the output of three-color fluorescent detection of a control sample processed the same way as Figure 3A, with no genomic DNA substrate in the amplification reaction.
Figures 4A and 4B are laser printed images of the results of fluorescent detection of the products of simultaneous amplification of the loci D3S1358,
D5S81 8, D7S820, D8S1 179, D1 3S317, D1 6S539, D1 8S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , G475, S1 59, and Amelogenin as detected using the fluorescein channel (Figure 4A) and carboxy-tetramethylrhodamine channel (Figure 4B) of a Hitachi FMBIO" II Fluorescent Scanner, as described in Example 4.
Figures 5A and 5B are laser printed images of the results of fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S81 8, D7S820, D8S1 1 79, D1 3S31 7, D1 6S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , G475, S1 59, and Amelogenin as detected using the fluorescein channel (Figure 5A) and carboxy-tetramethylrhodamine channel (Figure 5B) of a Hitachi FMBIOΦ II Fluorescent Scanner, as described in Example 5.
Figure 6A and 6B are laser printed images of the results of fluorescent detection of the products of simultaneous amplification of the loci D3S1358, D5S818, D7S820, D8S1 179, D1 3S317, D16S539, D18S51 , D21 S1 1 ,
HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, HUMvWFA31 , C221 , S159, and Amelogenin as detected using the fluorescein channel (Figure 6A) and carboxy-tetramethylrhodamine channel (Figure 6B) of a Hitachi FMBIO* II Fluorescent Scanner, as described in Example 6.
DETAILED DESCRIPTION OF THE INVENTION A. Definitions
The following definitions are intended to assist in providing a clear and consistent understanding of the scope and detail of the following terms, as used to describe and define the present invention: "Allelic ladder": a standard size marker consisting of amplified alleles from the locus.
"Allele": a genetic variation associated with a segment of DNA, i.e., one of two or more alternate forms of a DNA sequence occupying the same locus.
"Biochemical nomenclature": standard biochemical nomenclature is used herein in which the nucleotide bases are designated as adenine (A); thymine (T); guanine (G); and cytosine (C). Corresponding nucleotides are, for example, deoxyguanosine-5'-triphosphate (dGTP). "DNA polymorphism": the condition in which two or more different nucleotide sequences in a DNA sequence coexist in the same interbreeding population.
"Locus" or "genetic locus": a specific position on a chromosome. Alleles of a locus are located at identical sites on homologous chromosomes. "Locus-specific primer": a primer that specifically hybridizes with a portion of the stated locus or its complementary strand, at least for one allele of the locus, and does not hybridize efficiently with other DNA sequences under the conditions used in the amplification method.
"Pentanucleotide tandem repeat": a subclass of the STR polymorphisms defined below. Unless specified otherwise, the term "pentanucleotide tandem repeat" encompasses perfect STRs wherein the repeat unit is a five base sequence, and imperfect STRs wherein at least one repeat unit is a five base repeat.
"Polymerase chain reaction" or "PCR": a technique in which cycles of denaturation, annealing with primer, and extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence by approximately 106 times or more. The polymerase chain reaction process for amplifying nucleic acid is covered by U. S. Patent Nos. 4,683,195 and 4,683,202, which are incorporated herein by reference for a description of the process.
"Polymorphic short tandem repeat loci": STR loci, defined below, in which the number of repetitive sequence elements (and net length of sequence) in a particular region of genomic DNA varies from allele to allele, and from individual to individual.
"Polymorphism information content" or "PIC": a measure of the amount of polymorphism present at a locus (Botstein et al., 1980). PIC values range from 0 to 1 .0, with higher values indicating greater degrees of polymorphism.
This measure generally displays smaller values than the other commonly used measure, i.e., heterozygosity. For markers that are highly informative (heterozygosities exceeding about 70%), the difference between heterozygosity and PIC is slight.
"Primer": a single-stranded oligonucleotide or DNA fragment which hybridizes with a DNA strand of a locus in such a manner that the 3' terminus of the primer may act as a site of polymerization using a DNA polymerase enzyme.
"Primer pair": two primers including, primer 1 that hybridizes to a single strand at one end of the DNA sequence to be amplified and primer 2 that hybridizes with the other end on the complementary strand of the DNA sequence to be amplified. "Primer site": the area of the target DNA to which a primer hybridizes.
"Short tandem repeat loci" or "STR loci": regions of genomic DNA which contain short, repetitive sequence elements of 3 to 7 base pairs in length. The term STR also encompasses a region of genomic DNA wherein more than a single three to seven base sequence is repeated in tandem or with intervening bases, provided that at least one of the sequences is repeated at least two times in tandem. Each sequence repeated at least once within an STR is referred to herein as a "repeat unit."
The sequences of the STR loci analyzed using the materials and methods of the present invention can be divided into two general categories, perfect and imperfect. The term "perfect" STR, as used herein, refers to a region of double-stranded DNA containing a single three to seven base repeat unit repeated in tandem at least two times, e.g. (AAAAT)2. The term "imperfect" STR, as used herein, refers to a region of DNA containing at least two tandem repeats of a perfect repeat unit and at least one repeat of an imperfect repeat unit, wherein the imperfect repeat unit consists of a DNA sequence which could result from one, two, three, or four base insertions, deletions, or substitutions in the sequence of the perfect repeat unit, e.g. (AAAAT)12(AAAAAT)5AAT(AAATT)4. Every imperfect STR sequence contains at least one perfect STR sequence. Specifically, every STR sequence, whether perfect or imperfect, includes at least one repeat unit sequence appearing at least two times in tandem, a repeat unit sequence which can be represented by formula (I):
(AwG yC2)n (I) wherein A, G, T, and C represent the nucleotides which can be in any order; w, x, y and z represent the number of each nucleotide in the sequence and range from 0 to 7 with the sum of w + x + y + z ranging between 3 and 7; and n represents the number of times the sequence is tandemly repeated and is at least 2.
B. Selection of Multiplex Reaction Components The method of the present invention contemplates selecting an appropriate set of loci, primers, and amplification protocols to generate amplified alleles from multiple co-amplified loci which preferably do not overlap in size or, more preferably, which are labeled in a way which enables one to differentiate between the alleles from different loci which overlap in size. In addition, this method contemplates the selection of short tandem repeat loci which are compatible for use with a single amplification protocol. The specific combinations of loci described herein are unique in this application. Combinations of loci may be rejected for either of the above two reasons, or because, in combination, one or more of the loci do not produce adequate product yield, or fragments which do not represent authentic alleles are produced in this reaction. Successful combinations in addition to those disclosed herein can be generated by trial and error of locus combinations, by selection of primer pair sequences, and by adjustment of primer concentrations to identify an equilibrium in which all included loci may be amplified. Once the method and materials of this invention are disclosed, various methods of selecting loci, primer pairs, and amplification techniques for use in the method and kit of this invention are likely to be suggested to one skilled in the art. All such methods are intended to be within the scope of the appended claims.
Of particular importance in the practice of the method of this invention is the size range of amplified alleles produced from the individual loci which are co-amplified in the multiplex amplification reaction step. For ease of analysis with current technologies, systems which can be detected by amplification of fragments smaller than 500 bases are most preferable.
Practice of the method of the present invention begins with selection of a set of loci comprising at least thirteen STR loci, which can be co- amplified in a single multiplex amplification reaction. Selection of loci and oligonucleotide primers used to amplify the loci in the multiplex amplification reaction of the present method is described herein below, and illustrated in the Examples below.
C. Use of Multiplexes of Three Loci to Develop Multiplexes Using More than Three Loci
Any one of a number of different techniques can be used to select a set of loci for use in the present invention. One preferred technique for developing useful sets of loci for use in this method of analysis is described below. Once a multiplex containing three STR loci is developed, it may be used as a core to create multiplexes containing more than three loci. New combinations of more than three loci can, thus, be created which include the first three loci. For example, the core multiplex containing loci D7S820,
D1 3S317, and D5S818 was used to generate derivative multiplexes of:
D16S539, D7S820, D13S317, and D5S818; HUMCSF1PO, HUMTPOX, D16S539, D7S820, D13S317, and D5S818;
HUMCSF1PO, HUMTPOX, HUMTH01, D16S539, D7S820, D13S317, and D5S818; HUMCSF1PO, HUMTPOX, HUMTH01, HUMvWFA31, D16S539,
D7S820, D13S317, and D5S818;
D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D21S11, HUMCSF1PO, HUMFIBRA, HUMTH01, HUMTPOX, and HUMvWA31; S159, HUMCSF1PO, D16S539, D7S820, D13S317, and D5S818;
D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D21S11, HUMCSF1PO, HUMFIBRA, HUMTH01, HUMTPOX, and HUMvWFA31; and
D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D21S11, HUMCSF1PO, HUMFIBRA, HUMTH01, HUMTPOX,
HUMvWFA31, G475, S159, and Amelogenin.
It is contemplated that core sets of loci can be used to generate other appropriate derivative sets of STR loci for multiplex analysis using the method of this invention. Regardless of what method is used to select the loci analyzed using the method of the present invention, all the loci selected for multiplex analysis share the following characteristics: (1) they produce sufficient amplification product to allow evaluation; (2) they generate few if any artifacts due to the addition (or lack of addition) of a base to the amplified alleles during the multiplex amplification step; (3) they generate few, if any, artifacts due to premature termination of amplification reactions by a polymerase; and (4) they produce little or no "trailing" bands of smaller molecular weight from consecutive single base deletions below a given authentic amplified allele. See, e.g., Schumm et al., Fourth International
Symposium on Human Identification 1993. pp.177-187 (pub. by Promega Corp., 1994). The same technique used to identify the set of at least three loci, described above, can be applied to select thirteen or more loci of human genomic DNA or multiplex analysis, according to a preferred embodiment of the method of analysis of the present invention. Any set of loci identified as described above is suitable for multiplex analysis in accordance with the present invention, provided the set of loci comprises at least thirteen STR loci. More preferably, at least four of the at least thirteen STR loci analyzed according to the present invention are selected from the group of loci consisting of: D3S1 539, D4S2368, D5S818, D7S820, D9S930, D10S1239,
D1 3S317, D14S1 18, D14S548, D14S562, D16S490, D16S539, D16S753, D1 7S1298, D1 7S1 299, D19S253, D20S481 , D22S683, HUMCSF1 PO, HUMTPOX, HUMTH01 , HUMF13A01 , HUMBFXIII, HUMLIPOL, and HUMvWFA31 Even more preferably, the set of loci analyzed according to the present invention includes all thirteen CODIS loci, i.e. D3S1 358, D5S818, D7S820, D8S1 179, D1 3S317, D1 6S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 .
At least one of the loci selected for co-amplification in the present multiplex reaction is preferably an STR locus with a repeat unit of five to seven bases or base pairs in length, more preferably an STR locus with a pentanucleotide repeat. As is demonstrated in U.S. Patent Application Serial
Number 09/01 8,584, which is incorporated by reference herein, loci with such intermediate length repeats can be amplified with minimal incidence of artifacts, e.g. due to repeat slippage. Three such loci with pentanucleotide repeats, G475, C221 and S159, are included in the sets of loci identified immediately above. The terms "G475", "C221 ", and "S1 59", as used herein, refer to names assigned to pentanucleotide repeat loci identified, as described in U.S. Pat. App. Serial No. 09/018,584, incorporated by reference above. Each name corresponds to a clone from which each pentanucleotide locus was identified. The sequence of the G475 clone, described therein as SEQ ID NO:34, is identified herein as SEQ ID NO: 108. The sequence of the C221 clone, described therein as SEQ ID NO:2, is identified herein as SEQ ID NO: 109. The sequence of the S1 59 clone, described therein as SEQ ID NO: 26, is identified herein as SEQ ID NO: 1 10. Individual primers and primer pairs identified for use in amplifying G475, C221 , and SI 59 therein can also be used to amplify the same loci in the sets of at least thirteen loci co-amplified and analyzed according to the present invention.
The set of loci selected for co-amplification and analysis according to the invention preferably further comprises at least one locus in addition to the at least thirteen STR loci. The additional locus preferably includes a sequence polymorphism, or another feature which identifies a particular characteristic which separates the DNA of an individual from the DNA of other individuals in the population. The additional locus more preferably is a locus which identifies the gender of the source of the DNA sample analyzed. When the DNA sample is human genomic DNA, a gender identifying locus such as the
Amelogenin locus is preferably selected for co-amplification and analysis according to the present method. The Amelogenin locus is identified by GenBank as HUMAMELY (when used to identify a locus on the Y chromosome contained in male DNA) or as HUMAMELX (when used to identify a locus on the X chromosome in male or female DNA). When the
Amelogenin locus is co-amplified in the same multiplex amplification reaction as the set of at least thirteen short tandem repeat loci, the sequence of at least one of the primers used to amplify this particular locus in the multiplex amplification reaction preferably has a sequence selected from: SEQ ID NO:86, SEQ ID NO: 105, and SEQ ID NO:87.
D. Selection of Primers
Once a set of loci for co-amplification in a single multiplex reaction is identified, one can determine primers suitable for co-amplifying each locus in the set. Care should be used in selecting the sequence of primers used in the multiplex reaction. Inappropriate selection of primers can produce several undesirable effects such as lack of amplification, amplification at multiple sites, primer dimer formation, undesirable interaction of primer sequences from different loci, production of alleles from one locus which overlap with alleles from another, or the need for amplification conditions or protocols for the different loci which are incompatible in a multiplex. Primers used in the present method or included in the present kits of the invention are preferably selected according to the following selection process.
Primers are preferably developed and selected for use in the multiplex systems of the invention by employing a re-iterative process of selecting primer sequences, mixing the primers for co-amplification of the selected loci, co-amplifying the loci, then separating and detecting the amplified products. Initially, this process often produces the amplified alleles in an imbalanced fashion (i.e., higher product yield for some loci than for others) and may also generate amplification products which do not represent the alleles themselves. These extra fragments may result from any number of causes described above.
To eliminate such extra fragments from the multiplex systems, individual primers from the total set are used with primers from the same or other loci to identify which primers contribute to the amplification of the extra fragments. Once two primers which generate one or more of the fragments are identified, one or both contributors are modified and retested, either in a pair alone or in the multiplex system (or a subset of the multiplex system). This process is repeated until evaluation of the products yields amplified alleles with no or an acceptable level of extra fragments in the multiplex system.
On occasion, extra fragments can be eliminated by labeling the opposite primer in a primer pair. This change reveals the products of the opposing primer in the detection step. This newly labeled primer may amplify the true alleles with greater fidelity than the previously labeled primer generating the true alleles as a greater proportion of the total amplification product. The determination of primer concentration may be performed either before or after selection of the final primer sequences, but is preferably performed after that selection. Generally, increasing primer concentration for any particular locus increases the amount of product generated for that locus. However, this is also a re-iterative process because increasing yield for one locus may decrease it for one or more other loci. Furthermore, primers may interact directly affecting yield of the other loci. Linear increases in primer concentration do not necessarily produce linear increases in product yield for the corresponding locus. Locus to locus balance is also affected by a number of parameters of the amplification protocol such as the amount of template used, the number of cycles of amplification, the annealing temperature of the thermal cycling protocol, and the inclusion or exclusion of an extra extension step at the end of the cycling process. Absolutely even balance across all alleles and loci is generally not achieved.
The process of multiplex system development may also be a re-iterative process in another sense described, above. That is, it is possible, first, to develop a multiplex system for a small number of loci, this system being free or nearly free of extra fragments from amplification. Primers of this system may be combined with primers for one or more additional loci. This expanded primer combination may or may not produce extra fragments from amplification. In turn, new primers may be introduced and evaluated.
One or more of the re-iterative selection processes described above are repeated until a complete set of primers is identified which can be used to co- amplify the at least thirteen loci selected for co-amplification as described above. It is understood that many different sets of primers may be developed to amplify a particular set of loci.
Synthesis of the primers used in the present method can be conducted using any standard procedure for oligonucleotide synthesis known to those skilled in the art. At least one primer for each locus is preferably covalently attached to a dye label, as described in Section F, below. Table 1 , below, provides a list sequences of primers which have been determined to be suitable for use in amplifying the corresponding polymorphic STR loci listed therein. At least one primer listed in Table 1 is preferably used to amplify at least one of the loci selected for co-amplification and analysis as described above. It is understood that other primers could be identified which are suitable for simultaneous amplification of the loci listed below.
TABLE 1
Figure imgf000023_0001
Figure imgf000024_0001
E. Preparation of DNA Samples
Samples of genomic DNA can be prepared for use in the method of this invention using any method of DNA preparation which is compatible with the amplification of DNA. Many such methods are known by those skilled in the art. Examples include, but are not limited to DNA purification by phenol extraction (Sambrook, J., et al. (1 989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York., pp. 9.14-9.1 9), and partial purification by salt precipitation (Miller, S. et al. (1988) Nucl. Acids Res. 1 6:1 215) or chelex (Walsh et al., (1991 ) BioTechniques 10:506-513, Comey, et al., (1994) Forensic Sci. 39:1254) and the release of unpurified material using untreated blood (Burckhardt, J. (1994) PCR Methods and Applications 3:239-243, McCabe, Edward R.B.,(1991 ) PCR Methods and Applications 1 :99-106, Nordvag, Bjørn-Yngvar (1992) BioTechniques 12:4 pp. 490-492).
When the at least one DNA sample to be analyzed using the method of this invention is human genomic DNA, the DNA is preferably prepared from tissue, selected from the group consisting of blood, semen, vaginal cells, hair, saliva, urine, bone, buccal samples, amniotic fluid containing placental cells or fetal cells, chorionic villus, and mixtures of any of the tissues listed above.
Optionally, DNA concentrations can be measured prior to use in the method of the present invention, using any standard method of DNA quantification known to those skilled in the art. In such cases, the DNA concentration is preferably determined by spectrophotometric measurement as described by Sambrook, J., et al. (1 989), supra, Appendix E.5, or fluorometrically using a measurement technique such as that described by Brunk C. F., et al. (1979), Anal Biochem 92: 497-500. The DNA concentration is more preferably measured by comparison of the amount of hybridization of DNA standards with a human-specific probe such as that described by Waye, J.S., et al. (1991 ) "Sensitive and specific quantification of human genomic deoxyribonucleic acid (DNA) in forensic science specimens: casework examples," J. Forensic Sci., 36:1 198-1203. Use of too much template DNA in the amplification reactions can produce artifacts which appear as extra bands which do not represent true alleles.
F. Amplification of DNA
Once a sample of genomic DNA is prepared, the targeted loci can be co-amplified in the multiplex amplification step of the present method. Any one of a number of different amplification methods can be used to amplify the loci, including, but not limited to, polymerase chain reaction (PCR) (Saiki, R. K., et al. (1985), Science 230: 1350-1 354), transcription based amplification (Kwoh, D. Y., and Kwoh, T. J. (1990), American Biotechnology Laboratory, October, 1990) and strand displacement amplification (SDA) (Walker, G. T., et al. (1992) Proc. Natl. Acad. Sci., U.S.A. 89: 392-396).
Preferably, the DNA sample is subjected to PCR amplification using primer pairs specific to each locus in the set. Reference is made to the Sequence Listing at the end of this specification for details of the primer sequences used in the Examples below, some of which sequences are alternative embodiments of this invention. At least one primer for each locus is preferably covalently attached to a dye label, more preferably a fluorescent dye label. The primers and dyes attached thereto are preferably selected for the multiplex amplification reaction, such that alleles amplified using primers for each locus labeled with one color do not overlap the alleles of the other loci in the set co-amplified therein using primers labeled with the same color, when the alleles are separated, preferably, by gel or capillary electrophoresis.
In a particularly preferred embodiment of the method of the present invention, at least one primer for each locus co-amplified in the multiplex reaction is labeled with a fluorescent label prior to use in the reaction. Fluorescent labels suitable for attachment to primers for use in the present invention are commercially available. See, e.g. fluorescein and carboxy- tetramethylrhodamine labels and their chemical derivatives from PE Biosystems and Molecular Probes. Most preferably, at least three different labels are used to label the different primers used in the multiplex amplification reaction. When a size marker is included to evaluate the multiplex reaction, the primers used to prepare the size marker are preferably labeled with a different label from the primers used to amplify the loci of interest in the reaction.
Details of the most preferred amplification protocol for each of the most preferred combinations of loci for use in the method of this invention are given in the Examples below. Reference is also made to the Examples for additional details of the specific procedure relating to each multiplex. The sequences of the locus-specific primers used in the Examples include a number of nucleotides which, under the conditions used in the hybridization, are sufficient to hybridize with an allele of the locus to be amplified and to be essentially free from amplification of alleles of other loci. Reference is made to U.S. Patent 5,192,659 to Simons, the teaching of which is incorporated herein by reference for a more detailed description of locus-specific primers.
G. Separation and Detection of DNA Fragments Once a set of amplified alleles is produced from the multiplex amplification step of the present method, the amplified alleles are evaluated.
The evaluation step of this method can be accomplished by any one of a number of different means, the most preferred of which are described below.
Electrophoresis is preferably used to separate the products of the multiplex amplification reaction, more preferably capillary electrophoresis (see, e.g., Buel, Eric et al. (1998), Journal of Forensic Sciences; 43:(1 ) pp. 164- 1 70) or denaturing polyacrylamide gel electrophoresis (see, e.g., Sambrook, J. et al. (1989) In Molecular Cloning— A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, pp. 1 3.45-1 3.57). Gel preparation and electrophoresis procedures and conditions for suitable for use in the evaluating step of the method of this invention are illustrated in the Examples, below. Separation of DNA fragments in a denaturing polyacrylamide gel and in capillary electrophoresis occurs based primarily on fragment size.
Once the amplified alleles are separated, the alleles and any other DNA in the gel or capillary (e.g., DNA size markers or an allelic ladder) can then be visualized and analyzed. Visualization of the DNA in the gel can be accomplished using any one of a number of prior art techniques, including silver staining or reporters such as radioisotopes, fluorescers, chemiluminescers and enzymes in combination with detectable substrates. However, the preferred method for detection of multiplexes containing thirteen or more loci is fluorescence (see, e.g., Schumm, J. W. et al. in Proceedings from the Eighth International Symposium on Human Identification, (pub. 1998 by Promega Corporation), pp. 78-84; Buel, Eric et al. (1998), supra.), wherein primers for each locus in the multiplexing reaction is followed by detection of the labeled products employing a fluorometric detector. The references cited above, which describe prior art methods of visualizing alleles, are incorporated by reference herein.
The alleles present in the DNA sample are preferably determined by comparison to a size standard such as a DNA marker or a locus-specific allelic ladder to determine the alleles present at each locus within the sample. The most preferred size marker for evaluation of a multiplex amplification containing two or more polymorphic STR loci consists of a combination of allelic ladders for each of the loci being evaluated. See, e.g., Puers, Christoph et al., (1 993) Am J. Hum Genet. 53:953-958, Puers, Christoph, et al. (1994) Genomics 23:260-264. See also, U.S. Pat. No's 5,599,666; 5,674,686; and
5,783,406 for descriptions of allelic ladders suitable for use in the detection of STR loci, and methods of ladder construction disclosed therein.
Following the construction of allelic ladders for individual loci, these may be mixed and loaded for gel electrophoresis at the same time as the loading of amplified samples occurs. Each allelic ladder co-migrates with alleles in the sample from the corresponding locus.
The products of the multiplex reactions of the present invention can be evaluated using an internal lane standard, a specialized type of size marker configured to run in the same lane of a polyacrylamide gel or same capillary. The internal lane standard preferably consists of a series of fragments of known length. The internal lane standard more preferably is labeled with a fluorescent dye which is distinguishable from other dyes in the amplification reaction.
Following construction of the internal lane standard, this standard can also be mixed with amplified sample or allelic ladders and loaded for electrophoresis for comparison of migration in different lanes of gel electrophoresis or different capillaries of capillary electrophoresis. Variation in the migration of the internal lane standard indicates variation in the performance of the separation medium. Quantitation of this difference and correlation with the allelic ladders allows correction in the size determination of alleles in unknown samples. H. Preferred Detection Technique: Fluorescent Detection
In one of the most preferred embodiments of the method of this invention, fluorescent detection is used to evaluate the amplified alleles in the mixture produced by the multiplex amplification reaction. Below is a brief summary of how that method of detection preferably is practiced.
With the advent of automated fluorescent imaging, faster detection and analysis of multiplex amplification products can be achieved. For fluorescent analysis, one fluorescent labeled primer can be included in the amplification of each locus. Fluorescent labeled primers preferably suited for use in the present invention include the fluorescein-labeled (FL-), carboxy- tetramethylrhodamine-labeled (TMR-), and 5,6-carboxyrhodamine 6G-labeled (R6G) primers, such as are illustrated in the Examples, below. Separation of the amplified fragments produced using such labeled primers is achieved preferably by slab gel electrophoresis or capillary electrophoresis. The resulting separated fragments can be analyzed using fluorescence detection equipment such as an ABI PRISM* 310 Genetic Analyzer, an ABI PRISM* 377 DNA Sequencer (Applied Biosystems Division, Perkin Elmer, Foster City, CA), or a Hitachi FMBIO* II Fluorescent Scanner (Hitachi Software Engineering America, Ltd. South San Francisco, CA).
In summary, the method of this invention is most preferably practiced using fluorescent detection as the detection step. In this preferred method of detection, one or both of each pair of primers used in the multiplex amplification reaction has a fluorescent label attached thereto, and as a result, the amplified alleles produced from the amplification reaction are fluorescently labeled. In this most preferred embodiment of the invention, the amplified alleles are subsequently separated by capillary electrophoresis and the separated alleles visualized and analyzed using a fluorescent image analyzer. Fluorescent detection is preferred over radioactive methods of labeling and detection, because it does not require the use of radioactive materials, and all the regulatory and safety problems which accompany the use of such materials.
Fluorescent detection employing labeled primers is also preferred over other non-radioactive methods of detection, such as silver staining, because fluorescent methods of detection generally reveal fewer amplification artifacts than silver staining. The smaller number of artifacts are due, in part, to the fact that only amplified strands of DNA with labels attached are detected in fluorescent detection, while both strands of every amplified allele of DNA produced from the multiplex amplification reaction is stained and detected using the silver staining method of detection.
I. Kit
The present invention is also directed to kits that utilize the process described above. A basic kit comprises a container having one or more locus- specific primers. Instructions for use optionally may be included.
Other optional kit components may include an allelic ladder directed to each of the specified loci, a sufficient quantity of enzyme for amplification, amplification buffer to facilitate the amplification, loading solution for preparation of the amplified material for electrophoresis, genomic DNA as a template control, a size marker to insure that materials migrate as anticipated in the separation medium, and a protocol and manual to educate the user and to limit error in use. The amounts of the various reagents in the kits also can be varied depending upon a number of factors, such as the optimum sensitivity of the process. It is within the scope of this invention to provide test kits for use in manual applications or test kits for use with automated detectors or analyzers.
EXAMPLES The following Examples are presented to illustrate the advantages of the present invention and to assist one of ordinary skill in making and using the same. The Examples are intended to be illustrative, and are not intended in any way to otherwise limit the scope of the claims or protection granted by the patent.
The human genomic DNA samples assayed in the Example below were prepared from blood or tissue culture cells, using a standard procedure described by Miller and Dykes in (Miller, S. et al. ( 1 988) Nucl. Acids Res. 1 6: 1 21 5). The isolation and quantification methods described therein are generally known to those skilled in the art and are preferred, but not required, for application of the invention.
Each Example below is an example of the use of the method of this invention, to determine simultaneously the alleles present in at least thirteen loci from one or more DNA samples of human genomic DNA. Each set of loci co-amplified below includes the thirteen short tandem repeat loci identified for use in the CODIS system (i.e., D3S1358, HUMTH01 , D21 S1 1 , D18S51 , HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D1 3S317, D7S820, D16S539, and HUMCSF1 PO). Some sets of loci co-amplified below also include one or more additional short tandem repeat loci, such as loci with pentanucleotide repeats (e.g., G475, S1 59, or C221 ), and a non-STR locus, Amelogenin.
Table 2 summarizes which set of loci was co-amplified in the multiplex amplification reaction described in each Example below. The table also indicates which primer pair was used to amplify each such locus in each such multiplex reaction. One primer of each primer pair listed on Table 2 was fluorescently labeled prior to being used in the multiplex amplification reaction. In some cases, a different label was used to label primers to different loci, such that the alleles produced using the different primers could be distinguished from one another when detected with a laser-activated fluorescence detection device. Three different fluorescent labels were used in the Examples below, described as "FL" to indicate fluorescein-labeled, "TMR" to indicate carboxy- tetramethylrhodamine-labeled, and "R6G" to indicate 5,6-carboxyrhodamine 6G in Table 2, below. Table 2 also indicates which primer of each pair of primers used in the multiplex amplification reaction was so labeled in each Example (e.g., "FL-69" means the primer with SEQ ID NO:69 was labeled at its 5' end with fluorescein prior to being used in the multiplex amplification reaction). In the text of each of the Examples, however, the label abbreviation is placed immediately before the SEQ ID NO of the labeled primer used in the amplification reaction described therein (e.g., "FL-SEQ ID NO:2" instead of "FL-2").
TABLE 2
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
EXAMPLE 1
Fluorescent Detection of Multiplex Amplification of Loci D3S1358.
HUMTH01 . D21 S1 1 . D18S51 . HUMvWFA31 . D8S1 1 79. HUMTPOX.
HUMFIBRA. D5S81 8. D7S820. D1 3S317. D16S539. and HUMCSF1 PO as detected with the ABI PRISM* 310 Genetic Analyzer
In this Example, a DNA template was amplified simultaneously at the individual loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S81 8, D7S820, D13S317, D16S539, and HUMCSF1 PO in a single reaction vessel. The PCR amplification was performed in 25 μl of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH
8.3 at 25°C), 0.1 % Triton X-100, 1 .5mM MgCI2_ 1 60μg/ml BSA and 200μM each of dATP, dCTP, dGTP and dTTP) using 1 ng template, and 3.25 U AmpliTaq Gold™ DNA Polymerase. A GeneAmp* PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 12 min., then 10 cycles of 94°C for 30 sec, ramp for 68 sec. to 58°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 20 cycles of 90°C for 30 se , ramp 60 sec. to 58°C, hold for 30 sec, ramp for 50 sec, to 70°C, hold for 45 sec, followed by 1 cycle of 60°C for 30 min. Twenty-six amplification primers were used in combination, including
0.12μM each D3S1358 primers 1 [SEQ ID NO:68] and 2 [FL-SEQ ID NO:69], 0.08μM each HUMTH01 primers 1 [FL-SEQ ID NO:66] and 2 [SEQ ID NO:67], 0.3μM each D21 S1 1 primers 1 [SEQ ID NO:64] and 2 [FL-SEQ ID NO:65], 0.2μM each D18S51 primers 1 [FL-SEQ ID NO:62] and 2 [SEQ ID NO:63], 1 .1μM each HUMvWFA31 primers 1 [SEQ ID NO:76] and 2 [TMR-SEQ ID
N0:40], 1 .8μM each D8S1 179 primers 1 [SEQ ID N0:74] and 2 [TMR-SEQ ID NO:75], 0.6μM each HUMTPOX primers 1 [SEQ ID N0:72] and 2 [TMR- SEQ ID NO:73], 2.4μM each HUMFIBRA primers 1 [TMR-SEQ ID N0:70] and 2 [SEQ ID N0:71 ], 0.2μM each D5S818 primers 1 [SEQ ID N0:84] and 2 [R6G-SEQ ID N0:85], 0.1μM each D13S317 primers 1 [SEQ ID NO:82] and
2 [R6G-SEQ ID NO:83], 0.2μM each D7S820 primers 1 [R6G-SEQ ID NO:80] and 2 [SEQ ID NO:81 ], 0.1 5μM each D1 6S539 primers 1 [SEQ ID NO:29] and 2 [R6G-SEQ ID NO:79], 0.2μM each HUMCSF1 P0 primers 1 [SEQ ID NO:77] and 2 [R6G-SEQ ID NO:78]
Amplified products were separated using an ABI PRISM* 310 Genetic Analyzer. DNA samples were mixed with 24μl of a loading solution
(deionized formamide) and 1 .Oμl of an internal lane size standard, denatured at 95°C for 3 min., and chilled on ice prior to injection. Separation was carried out using Performance Optimized Polymer 4 (POP-4)(Perkin Elmer Biosystems, Foster City, CA) in a 47cm x 50μm capillary. The manufacturer's GeneScan* run module GS STR P0P4 (Id.) (1 ml) A was used.
Conditions for the electrophoresis were a 5 second injection, injection kV was 15.0, run kV was 1 5.0, run temperature was 60°C, run time was 28 minutes and virtual filter A was used.
Figure 1 A is a printout of results of scanning the amplified fragments of each locus separated and detected with the ABI PRISM* 310 Genetic
Analyzer, as described above. Figure 1 A shows amplification products of a DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, and HUMCSF1 PO. Peaks shown in Panel A are labeled with fluorescein, peaks shown in Panel B are labeled with carboxy-tetramethylrhodamine, and peaks shown in Panel C are labeled with 5,6 carboxyrhodamine 6G.
Figure 1 B is a printout of the results of scanning a sample prepared in the same way as the sample scanned in Figure 1 A, except that no DNA template was used in the amplification reaction. Peaks in this figure are background products resulting from dye conjugation and purification procedures and from undefined causes. EXAMPLE 2
Fluorescent Detection of Multiplex Amplification of Loci D3S1 358. HUMTH01 . D21 S1 1 . D18S51 . G475. Amelogenin. HUMvWFA31 . D8S1 1 79. HUMTPOX. HUMFIBRA. D5S81 8. D7S820. D13S317. D1 6S539. HUMCSF1 PO. and S1 59 as detected with the ABI PRISM* 310
Genetic Analyzer
In this Example, a DNA template was amplified simultaneously at the individual loci D3S1 358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S81 8, D7S820,
D13S317, D16S539, HUMCSF1 PO and S159 in a single reaction vessel. The PCR amplification was performed in 25μl of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25° C), 0.1 % Triton X-100, 1 .5mM MgCI2, 160μg/ml BSA and 200μM each of dATP, dCTP, dGTP and dTTP) using 1 ng template, and 4 U AmpliTaq Gold™ DNA Polymerase. A GeneAmp* PCR
System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 12 min., then 10 cycles of 94°C for 30 sec, ramp for 68 sec. to 58°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 20 cycles of 90°C for 30 sec, ramp 60 sec. to 58°C, hold for 30 sec, ramp for 50 sec, to 70°C, hold for 45 sec, followed by 1 cycle of 60°C for 30 min.
Thirty-two amplification primers were used in combination, including 0.12μM each D3S1358 primers 1 [SEQ ID NO:68] and 2 [FL-SEQ ID NO:69], 0.08μM each HUMTH01 primers 1 [FL-SEQ ID NO:66] and 2 [SEQ ID NO:67], 0.3μM each D21 S1 1 primers 1 [SEQ ID NO:64] and 2 [FL-SEQ ID NO:65],
0.2μM each D18S51 primers 1 [FL-SEQ ID NO:62] and 2 [SEQ ID NO:63], 0.24μM each G475 primers 1 [FL-SEQ ID NO:88] and 2 [SEQ ID NO:89], 0.6μM each Amelogenin primers 1 [TMR-SEQ ID NO:86] and 2 [SEQ ID NO:87], 1 .1μM each HUMvWFA31 primers 1 [SEQ ID NO:76] and 2 [TMR- SEQ ID N0:40], 1 .8μM each D8S1 179 primers 1 [SEQ ID NO:74] and 2
[TMR-SEQ ID NO:75], 0.6μM each HUMTPOX primers 1 [SEQ ID NO:72] and 2 [TMR-SEQ ID NO:73], 2.4μM each HUMFIBRA primers 1 [TMR-SEQ ID NO:70] and 2 [SEQ ID NO:71 ], 0.2μM each D5S81 8 primers 1 [SEQ ID NO:84] and 2 [R6G-SEQ ID NO:85], 0.1 μM each D1 3S31 7 primers 1 [SEQ ID NO:82] and 2 [R6G-SEQ ID NO:83], 0.2μM each D7S820 primers 1 [R6G- SEQ ID N0:80] and 2 [SEQ ID N0:81 ], 0.1 5μM each D1 6S539 primers 1
[SEQ ID NO:29] and 2 [R6G-SEQ ID NO:79], 0.2μM each HUMCSF1 PO primers 1 [SEQ ID NO:77] and 2 [R6G-SEQ ID NO:78] 0.1 μM each S1 59 primers 1 [SEQ ID NO:90] and 2 [R6G-SEQ ID NO:91 ]
Amplified products were separated using an ABI PRISM* 310 Genetic Analyzer. DNA samples were mixed with 24μl of a loading solution
(deionized formamide) and 1 .Oμl of an internal lane size standard, denatured at 95°C for 3 min., and chilled on ice prior to injection. Separation was carried out using Performance Optimized Polymer 4 (POP-4) (Perkin Elmer Biosystems, Foster City, CA) in a 47cm x 50μm capillary. The manufacturer's GeneScan* run module GS STR P0P4 (/c/.)(1 ml) A was used.
Conditions for the electrophoresis were a 5 second injection, injection kV was 1 5.0, run kV was 1 5.0, run temperature was 60°C, run time was 28 minutes and virtual filter A was used.
Figure 2A is a printout of results of scanning the amplified fragments of each locus separated and detected with the ABI PRISM* 310 Genetic
Analyzer, as described above. Figure 2A shows amplification products of a DNA sample simultaneously co-amplified for the loci D3S1 358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D1 3S317, D16S539, HUMCSF1 PO, and S159. Peaks shown in Panel A are labeled with fluorescein, peaks shown in
Panel B are labeled with carboxy-tetramethylrhodamine, and peaks shown in Panel C are labeled with 5,6 carboxyrhodamine 6G.
Figure 2B is a printout of the results of scanning a sample prepared in the same way as the sample scanned in Figure 2A, except that no DNA template was used in the amplification reaction. Peaks in this figure are background products resulting from dye conjugation and purification procedures and from undefined causes.
EXAMPLE 3 Fluorescent Detection of Multiplex Amplification of Loci D3S1 358.
HUMTH01 . D21 S1 1 . D18S51 . G475. Amelogenin. HUMvWFA31 . D8S1 179. HUMTPOX. HUMFIBRA. D5S81 8. D7S820. D13S31 7. D1 6S539. HUMCSF1 PO. and S1 59 as detected with the ABI PRISM* 377
DNA Sequencer
In this Example, a DNA template was amplified as in Example 2. Amplified products were separated using an ABI PRISM* 377 DNA Sequencer. This was carried out using a 0.2mm thick, 5% Long Ranger™ Acrylamide (FMC BioProducts, Rockland, ME), 7M urea gel. DNA samples were mixed with 1 .5μl of a loading solution (88.25% formamide, 4.1 mM EDTA, 1 5mg/ml
Blue Dextran) and O.δμl of an internal lane size standard, denatured at 95°C for 2 min., and chilled on ice prior to loading. Electrophoresis was carried out using the manufacturer's GeneScan* modules for Prerun (PR GS 36A-2400) and Run (GS 36A-2400). Run time was 3 hours and virtual filter A was used. Figure 3A is a printout of results of scanning the amplified fragments of each locus separated and detected with the ABI PRISM* 377 DNA Sequencer, as described above. Figure 3A shows amplification products of a DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO, and
S1 59. Peaks shown in Panel A are labeled with fluorescein, peaks shown in Panel B are labeled with carboxy-tetramethylrhodamine, and peaks shown in Panel C are labeled with 5,6 carboxyrhodamine 6G.
Figure 3B is a printout of the results of scanning a sample prepared in the same way as the sample scanned in Figure 3A, except that no DNA template was used in the amplification reaction. Peaks in this figure are background products resulting from dye conjugation and purification procedures and from undefined causes.
EXAMPLE 4 Fluorescent Detection of Multiplex Amplification of Loci D3S1 358.
HUMTH01 . D21 S1 1 . D18S51 . G475. Amelogenin. HUMvWFA31 . D8S1 179. HUMTPOX. HUMFIBRA. D5S81 8. D7S820. D1 3S31 7. D1 6S539. HUMCSF1 PP. and S1 59 as detected with the Hitachi FMBIO* II
Fluorescent Scanner
In this example, two DNA templates were each amplified simultaneously at each of three different locus combinations selected from the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin,
HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S31 7, D16S539, HUMCSF1 PO and S1 59. Amplification of each locus combination included 5ng template in a single reaction vessel containing 25μl of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 %
Triton X-100, 1 .5mM MgCI2 160//g/ml BSA and 200 yM each of dATP, dCTP, dGTP and dTTP). A GeneAmp* PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 1 2 min., then
10 cycles of 94°C for 30 sec, ramp for 68 sec. to 58°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 22 cycles of 90°C for
30 sec, ramp 60 sec. to 58°C, hold for 30 sec, ramp for 50 sec, to 70°C, hold for 45 sec, followed by 1 cycle of 60°C for 30 min.
Thirty-two amplification primers were used in the following concentrations, including 0.225 yM each D3S1358 primers 1 [SEQ ID NO:68] and 2 [FL-SEQ ID NO:69], 0.2/.M each HUMTH01 primers 1 [FL-SEQ ID NO:66] and 2 [SEQ ID NO:67], 1.0 M each D21 S1 1 primers 1 [SEQ ID NO:64] and 2 [FL-SEQ ID N0:65], 1 .OμM each D18S51 primers 1 [FL-SEQ
ID NO:62] and 2 [SEQ ID NO:63], 2.8 /M each G475 primers 1 [FL-SEQ ID NO:88] and 2 [SEQ ID NO:89], 0.2 M each Amelogenin primers 1 [TMR-SEQ ID NO:86] and 2 [SEQ ID NO:87], 0.3 /M each HUMvWFA31 primers 1 [SEQ ID NO:76] and 2 [TMR-SEQ ID N0:40], 1 .5 .M each D8S1 179 primers 1 [SEQ ID NO:74] and 2 [TMR-SEQ ID NO:75], 0.2μM each HUMTPOX primers 1 [SEQ ID NO:72] and 2 [TMR-SEQ ID NO:73], 2.0/.M each HUMFIBRA primers
1 [TMR-SEQ ID NO:70] and 2 [SEQ ID NO:71 ], 0.55//M each D5S818 primers 1 [SEQ ID NO:84] and 2 [FL-SEQ ID NO:85], 1 .1 M each D1 3S317 primers 1 [SEQ ID NO:82] and 2 [FL-SEQ ID NO:83], 1 .7//M each D7S820 primers 1 [FL-SEQ ID NO:80] and 2 [SEQ ID NO:81 ], 3.3μM each D16S539 primers 1 [SEQ ID NO:29] and 2 [FL-SEQ ID NO:79], O.δμM each HUMCSF1 PO primers
1 [SEQ ID NO:77] and 2 [FL-SEQ ID NO:78], 2.0 M each S1 59 primers 1 [SEQ ID NO:90] and 2 [FL-SEQ ID NO:91 ],
In the first locus combination, each template was amplified using 2.5 U of AmpliTaq Gold™ DNA Polymerase and primers for each locus used in the concentrations described above for the loci D3S1 358, HUMTH01 , D21 S1 1 ,
D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA. In the second locus combination, all thirty-two primers, above, at the described concentrations, and 4 U of AmpliTaq Gold™ DNA Polymerase were used to amplify DNA templates at all sixteen loci, D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179,
HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and S1 59 in a single reaction vessel. In the third combination, each template was amplified using 1 .5 U of AmpliTaq Gold™ DNA Polymerase and primers for each locus used in the concentrations described above for the loci D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and
S1 59.
Amplification products were separated by electrophoresis through a 0.4 mm thick 4% denaturing polyacrylamide gel (19:1 ratio of acrylamide to bis- acrylamide) which contained 7 M urea (Sambrook et al., (1989)), and which was chemically cross-linked to 2 glass plates (Kobayashi, Y. (1988), BRL
Focus 10: 73-74). DNA samples were mixed with 3.5μl of a loading solution (10mM NaOH, 95% formamide, 0.05% bromophenol blue) and 0.5μl of an internal lane size standard, denatured at 95°C for 2 min., and chilled on ice prior to loading. The separated products were visualized by detection of the fluorescent signals using the Hitachi FMIBO* II fluorescent scanner (Hitachi Software Engineering America, Ltd. South San Francisco, CA). Band pass filters at 505 nm and 585 nm, respectively, were used for the detection of fluorescein-labeled loci and carboxy-tetramethylrhodamine-labeled loci, respectively. A band pass filter of 650nm was used for detection of the internal lane standard (size standard data, not shown). Reference is made to Figures 4A and 4B, which display the fragments resulting from each amplification reaction. Figure 4A shows the results from the 505 nm scan (Fluorescein channel) and Figure 4B shows the results from the 585 nm scan (carboxy-tetramethylrhodamine channel) of the same lanes of the polyacrylamide gel. For each DNA template, lane 1 shows the results of the DNA sample which has been simultaneously co-amplified for the loci
D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA. Lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D1 3S317, D7S820, D1 6S539, HUMCSF1 PO, and
S1 59. Lane 3 shows the results of the DNA sample simultaneously co- amplified for the loci D5S818, D13S317, D7S820, D16S539, HUMCSF1 PO, and S1 59.
EXAMPLE 5
Fluorescent Detection of Multiplex Amplification of Loci D3S1 358.
HUMTH01 . D21 S1 1 . D18S51 . G475. Amelogenin. HUMvWFA31 .
D8S1 179. HUMTPOX. HUMFIBRA. D5S818. D7S82Q. D1 3S317.
D16S539. HUMCSF1 PO. and SI 59 as detected with the Hitachi FMBIO* II Fluorescent Scanner In this example, two DNA templates were each amplified simultaneously at each of two different locus combinations selected from the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin,
HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and S159. Amplification of each locus combination included 5ng template in a single reaction vessel containing 25μl of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 %
Triton X-100, 1 .5mM MgCI2, 160μg/ml BSA and 200μM each of dATP, dCTP, dGTP and dTTP). A GeneAmp* PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 12 min., then
10 cycles of 94°C for 30 sec, ramp for 68 sec. to 58°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 22 cycles of 90°C for
30 sec, ramp 60 sec. to 58°C, hold for 30 sec, ramp for 50 sec, to 70°C, hold for 45 sec, followed by 1 cycle of 60° C for 30 min.
Thirty-two amplification primers were used in the following concentrations, including 0.225μM each D3S1358 primers 1 [SEQ ID NO:68] and 2 [FL-SEQ ID NO:69], 0.2μM each HUMTH01 primers 1 [FL-SEQ ID NO:66] and 2 [SEQ ID NO:67], 1 .OμM each D21 S1 1 primers 1 [SEQ ID NO:64] and 2 [FL-SEQ ID NO:65], 1 .OμM each D1 8S51 primers 1 [FL-SEQ
ID NO:62] and 2 [SEQ ID NO:63], 2.8μM each G475 primers 1 [SEQ ID NO:88] and 2 [FL-SEQ ID N0:94], 0.2μM each Amelogenin primers 1 [TMR- SEQ ID NO:86] and 2 [SEQ ID NO:87], 0.3μM each HUMvWFA31 primers 1 [SEQ ID NO:76] and 2 [TMR-SEQ ID N0:40], 1 .5μM each D8S1 179 primers 1 [SEQ ID N0:74] and 2 [TMR-SEQ ID NO:75], 0.2μM each HUMTPOX primers 1 [SEQ ID NO:72] and 2 [TMR-SEQ ID NO:73], 2.0μM each HUMFIBRA primers 1 [TMR-SEQ ID NO:70] and 2 [SEQ ID NO:71 ], 0.55μM each D5S818 primers 1 [SEQ ID NO:84] and 2 [FL-SEQ ID NO:85], 1 .1μM each D13S317 primers 1 [SEQ ID NO:82] and 2 [FL-SEQ ID NO:83], 1 .7μM each D7S820 primers 1 [FL-SEQ ID NO:80] and 2 [SEQ ID NO:81 ], 3.3μM each D16S539 primers 1 [SEQ ID NO:29] and 2 [FL-SEQ ID NO:79], 0.5μM each HUMCSF1 PO primers 1 [SEQ ID NO:77] and 2 [FL-SEQ ID NO:78], 2.0μM each S1 59 primers 1 [SEQ ID NO:95] and 2 [FL-SEQ ID NO:96].
In the first locus combination, each template was amplified using 2.5 U of AmpliTaq Gold™ DNA Polymerase and primers for each locus used in the concentrations described above for the loci D3S1358, HUMTH01 , D21 S1 1 ,
D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA. In the second locus combination, all thirty-two primers, above, at the described concentrations, and 4 U of AmpliTaq Gold™ DNA Polymerase were used to amplify DNA templates at all sixteen loci, D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179,
HUMTPOX, HUMFIBRA, D5S81 8, D7S820, D1 3S317, D1 6S539, HUMCSF1 PO and S1 59 in a single reaction vessel.
The separation and visualization of amplified products were as described in Example 4. Reference is made to Figure 5A and 5B, which display the fragments resulting from each amplification reaction. Figure 5A shows the results from the 505 nm scan (Fluorescein channel) and Figure 5B shows the results from the 585 nm scan (carboxy-tetramethylrhodamine channel) of the same lanes of the polyacrylamide gel. For each template, lane 1 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 ,
D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA and lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D13S317, D7S820, D16S539, HUMCSF1 PO, and
S159. EXAMPLE 6
Fluorescent Detection of Multiplex Amplification of Loci D3S1 358. HUMTH01 . D21 S1 1 . D1 8S51 . S1 59. Amelogenin. HUMvWFA31 . D8S1 179. HUMTPOX. HUMFIBRA. D5S81 8. D7S820. D1 3S317. D16S539. HUMCSF1 PO. and C221 as detected with the Hitachi FMBIO* II
Fluorescent Scanner
In this example, two DNA templates were each amplified simultaneously at each of three different locus combinations selected from the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , S159, Amelogenin,
HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and C221 . Amplification of each locus combination included 10ng template in a single reaction vessel containing 25μl of 1 x Gold ST*R Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 % Triton X-100, 1 .5mM MgCI2> 160μg/ml BSA and 200μM each of dATP, dCTP, dGTP and dTTP).
A GeneAmp* PCR System 9600 (Perkin Elmer, Foster City, CA) was employed with the following amplification protocol: 96°C for 1 2 min., then 10 cycles of 94°C for 30 sec, ramp for 68 sec. to 60°C, hold for 30 sec, ramp 50 sec. to 70°C, hold for 45 sec, followed by 20 cycles of 90°C for
30 sec, ramp 60 sec. to 60°C, hold for 30 sec, ramp for 50 sec, to 70°C, hold for 45 sec, followed by 1 cycle of 60°C for 30 min.
Thirty-two amplification primers were used in the following concentrations, including 0.75μM each D3S1358 primers 1 [SEQ ID NO: 106] and 2 [FL-SEQ ID NO:69], 0.3μM each HUMTH01 primers 1 [FL-SEQ ID
NO:38] and 2 [SEQ ID NO: 103], 2.0μM each D21 S1 1 primers 1 [SEQ ID NO:64] and 2 [FL-SEQ ID NO:65], 0.3μM each D18S51 primers 1 [FL-SEQ ID NO: 101 ] and 2 [SEQ ID NO:102], 2.0μM each S1 59 primers 1 [SEQ ID NO:92] and 2 [FL-SEQ ID NO:93], 0.1 5μM each Amelogenin primers 1 [TMR- SEQ ID NO: 105] and 2 [SEQ ID NO:87], 1 .OμM each HUMvWFA31 primers
1 [SEQ ID NO:76] and 2 [TMR-SEQ ID N0:40], 1 .25μM each D8S1 179 primers 1 [TMR-SEQ ID NO:104] and 2 [SEQ ID NO:75], 0.75μM each HUMTPOX primers 1 [TMR-SEQ ID NO:72] and 2 [SEQ ID NO:73], 1 .5μM each HUMFIBRA primers 1 [TMR-SEQ ID NO:70] and 2 [SEQ ID NO: 107], 0.55μM each D5S818 primers 1 [SEQ ID NO:84] and 2 [FL-SEQ ID NO:85], 1 .1μM each D13S317 primers 1 [SEQ ID NO:3] and 2 [FL-SEQ ID N0:4],
1 .7μM each D7S820 primers 1 [FL-SEQ ID N0:80] and 2 [SEQ ID NO:81 ], 3.3μM each D16S539 primers 1 [FL-SEQ ID NO:29] and 2 [SEQ ID NO:97], 0.25μM each HUMCSF1 PO primers 1 [SEQ ID NO:77] and 2 [FL-SEQ ID NO:98], 1 .0μM each C221 primers 1 [FL-SEQ ID NO:99] and 2 [SEQ ID NO: 100].
In the first locus combination, each template was amplified using 2.5 U of AmpliTaq Gold™ DNA Polymerase and primers for each locus used in the concentrations described above for the loci D3S1358, HUMTH01 , D21 S1 1 , D1 8S51 , S1 59, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA. In the second locus combination, all thirty-two primers, above, at the described concentrations and 4 U of AmpliTaq Gold™ DNA Polymerase were used to amplify DNA templates at all sixteen loci, D3S1358, HUMTH01 , D21 S1 1 , D18S51 , S159, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and C221 in a single reaction vessel. In the third combination, each template was amplified using 1 .5 U of AmpliTaq Gold™ DNA Polymerase and primers for each locus used in the concentrations described above for the loci D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO and C221 .
The amplification products were separated and detected as described in Example 4, except that each sample of amplification products was diluted
1 :4 in 1 x STR Buffer (50mM KCI, 10mM Tris-HCI (pH 8.3 at 25°C), 0.1 % Triton X-100, 1 .5mM MgCI2, and 200μM each of dATP, dCTP, dGTP and dTTP). The diluted amplification products (2.5μl) were mixed with 2.5μl of a loading solution (10mM NaOH, 95% formamide, 0.05% bromophenol blue), without an internal lane standard, denatured at 95°C for 2 min., and chilled on ice prior to loading. Reference is made to Figures 6A and 6B, which display the fragments resulting each amplification reaction. Figure 6A shows the results from the 505 nm scan (Fluorescein channel) and Figure 6B shows the results from the 585 nm scan (carboxy-tetramethylrhodamine channel) of the same lanes of the polyacrylamide gel. For each DNA template, lane 1 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1358, HUMTH01 , D21 S1 1 , D18S51 , S159, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, and HUMFIBRA. Lane 2 shows the results of the DNA sample simultaneously co-amplified for the loci D3S1 358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX,
HUMFIBRA, D5S818, D1 3S317, D7S820, D16S539, HUMCSF1 PO, and C221 . Lane 3 shows the results of the DNA sample simultaneously co- amplified for the loci D5S818, D13S317, D7S820, D16S539, HUMCSF1 PO, and C221 .

Claims

CLAIMSWhat is claimed is:
1 . A method of simultaneously determining the alleles present in a set of loci from one or more DNA samples, comprising: (a) obtaining at least one DNA sample to be analyzed,
(b) selecting a set of loci of the DNA sample, comprising at least thirteen short tandem repeat loci which can be co-amplified,
(c) co-amplifying the loci in the set in a multiplex amplification reaction, wherein the product of the reaction is a mixture of amplified alleles from each of the co-amplified loci in the set; and
(d) evaluating the amplified alleles in the mixture to determine the alleles present at each of the loci analyzed in the set within the DNA sample.
2. The method of claim 1 , wherein at least four of the at least thirteen short tandem repeat loci are selected from the group consisting of:
D3S1539, D4S2368, D5S818, D7S820, D9S930, D10S1239,
D13S317, D14S118, D14S548, D14S562, D16S490, D16S539,
D16S753, D17S1298, D17S1299, D19S253, D20S481, D22S683, HUMCSF1PO, HUMTPOX, HUMTH01, HUMF13A01, HUMBFXIII, HUMLIPOL, HUMvWFA31.
3. The method of claim 2, wherein the set of loci selected in step (b) comprise the thirteen short tandem repeat loci D3S1358, D5S818, D7S820, D8S1 179, D1 3S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO,
HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 .
4. The method of claim 1 , wherein at least one of the at least thirteen short tandem repeat loci in the set of loci selected in step (b) is a pentanucleotide tandem repeat locus.
5. The method of claim 4, wherein the pentanucleotide tandem repeat locus is selected from the group consisting of G475, C221 , and S1 59.
6. The method of claim 1 , wherein the set of loci selected in step (b) further comprises a locus which can be used to identify the gender of at least one source of the DNA provided in step (a).
7. The method of claim 6, wherein the at least one source of the DNA provided in step (a) is a human being, and the locus used to identify the gender of the human being is an Amelogenin locus.
8. The method of claim 7, wherein the Amelogenin locus is co- amplified using an oligonucleotide primer having a sequence selected from the group consisting of SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO: 105.
9. The method of claim 1 , wherein the multiplex amplification reaction is done using at least one oligonucleotide primer having a sequence selected from at least one of the groups of sequences consisting of:
SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:80 and SEQ ID NO:81 , when one of the loci in the set is D7S820;
SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:82, and SEQ ID NO:83, when one of the loci in the set is D13S317;
SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:84, and SEQ ID NO:85, when one of the loci in the set is D5S818; SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:49, when one of the loci in the set is D3S1 539;
SEQ ID NO:9, SEQ ID NO: 10, when one of the loci in the set is D1 7S1 298;
SEQ ID NO: 1 1 , SEQ ID O:12, SEQ ID NO:52, SEQ ID NO: 53, when one of the loci in the set is D20S481 ; SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO: 55, SEQ ID NO: 61 , when one of the loci in the set is D9S930;
SEQ ID NO:1 5, SEQ ID NO:16, SEQ ID NO:54, when one of the loci in the set is D10S1239; SEQ ID NO:17, SEQ ID NO: 1 8, when one of the loci in the set is
D14S1 18;
SEQ ID NO:19, SEQ ID NO:20, when one of the loci in the set is D14S562;
SEQ ID NO:21 , SEQ ID NO:22, when one of the loci in the set is D14S548;
SEQ ID NO:23, SEQ ID NO:24, when one of the loci in the set is D16S490;
SEQ ID NO:25, SEQ ID NO:26, when one of the loci in the set is D16S753; SEQ ID NO:27, SEQ ID NO:28, when one of the loci in the set is
D17S1299;
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:58, SEQ ID NO:79, and SEQ ID NO:97, when one of the loci in the set is D16S539;
SEQ ID NO:31 , SEQ ID NO:32, when one of the loci in the set is D22S683;
SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:98, when one of the loci in the set is HUMCSF1 PO;
SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:72 and SEQ ID NO:73, when one of the loci in the set is HUMTPOX; SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:66, SEQ ID NO:67, and
SEQ ID NO: 103, when one of the loci in the set is HUMTH01 ;
SEQ ID NO:39, SEQ ID N0:40, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:76 when one of the loci in the set is HUMvWFA31
SEQ ID N0:41 , SEQ ID NO:42, when one of the loci in the set is HUMF13A01 ; SEQ ID NO-.43, SEQ ID N0:44, when one of the loci in the set is HUMFESFPS;
SEQ ID NO:45, SEQ ID NO:46, when one of the loci in the set is HUMBFXIII; SEQ ID NO:47, SEQ ID NO:48, when one of the loci in the set is
HUMLIPOL;
SEQ ID NO:50, SEQ ID NO:51 , when one of the loci in the set is D1 9S253; and
SEQ ID NO:56, SEQ ID NO:57, when one of the loci in the set is D4S2368.
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO: 101 , and SEQ ID NO: 102, when one of the loci in the set is D1 8S51 ;
SEQ ID NO:64 and SEQ ID NO:65, when one of the loci in the set is D21 S1 1 ; SEQ ID NO:68, SEQ ID NO:69, and SEQ ID NO: 106, when one of the loci in the set is D3S1538;
SEQ ID NO:70, SEQ ID NO:71 , and SEQ ID NO:107, when one of the loci in the set is HUMFIBRA;
SEQ ID NO:74, SEQ ID NO:75, and SEQ ID NO:104, when one of the loci in the set is D8S1 179;
SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO:105, when one of the loci in the set is Amelogenin;
SEQ ID NO:88, SEQ ID NO:89, and SEQ ID N0:94, when one of the loci in the set is G475; SEQ ID NO:90, SEQ ID NO:91 , SEQ ID NO:92, SEQ ID NO:93, SEQ ID
NO:95, and SEQ ID NO:96, when one of the loci in the set is S1 59; and
SEQ ID NO:99 and SEQ ID NO: 100, when one of the loci in the set is C221.
10. The method of claim 1 , wherein the amplified alleles are separated prior to evaluating in step (d), using a separation means selected from the group consisting of polyacrylamide gel electrophoresis and capillary gel electrophoresis.
1 1 . The method of claim 1 , wherein the multiplex amplification reaction is done using at least thirteen pairs of oligonucleotide primers flanking the at least thirteen loci analyzed.
12. The method of claim 1 1 , wherein the set of loci is co-amplified using a polymerase chain reaction.
1 3. The method of claim 1 1 , wherein each of the loci co-amplified in the multiplex reaction in step (b) is co-amplified using a pair of primers which flank the locus, wherein at least one primer of each pair has a fluorescent label covalently attached thereto.
14. The method of claim 13, wherein at least three of the labeled primers have different fluorescent labels covalently attached thereto.
1 5. The method of claim 1 wherein the at least one DNA sample to be analyzed is prepared from human tissue, wherein the human tissue is selected from the group of human tissue consisting of blood, semen, vaginal cells, hair, saliva, urine, amniotic fluid containing placental cells or fetal cells, and mixtures of any of the tissues listed above.
16. The method of claim 1 , wherein the amplified alleles are evaluated by comparing the amplified alleles to a size standard, wherein the size standard is selected from the group of size standards consisting of a DNA marker and a locus-specific allelic ladder.
17. A method of simultaneously identifying the alleles present in a set of loci of from one or more DNA samples, comprising: (a) obtaining at least one DNA sample to be analyzed,
(b) selecting a set of loci of the DNA sample, comprising short tandem repeat loci D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D1 8S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 , HUMTPOX, and HUMvWFA31 ;
(c) co-amplifying the loci in the set in a multiplex amplification reaction, wherein the product of the reaction is a mixture of amplified alleles from each of the co-amplified loci in the set; and
(d) evaluating the amplified alleles in the mixture to determine the alleles present at each of the loci analyzed in the set within the DNA sample.
1 8. The method of claim 1 7, wherein the multiplex amplification reaction is done using at least one primer for at least one locus in the set of at least thirteen loci selected in step (b), wherein the primer has a sequence selected from one of the groups of primer sequences consisting of:
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:101 , and SEQ ID NO:102, when one of the loci in the set is D18S51 ;
SEQ ID NO:64 and SEQ ID NO:65, for the locus D21 S1 1 ; SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:66, SEQ ID NO:67, and
SEQ ID NO: 103, for the locus HUMTH01 ;
SEQ ID NO:68, SEQ ID NO:69, and SEQ ID NO: 106, for the locus D3S1358;
SEQ ID NO:70, SEQ ID NO:71 ,and SEQ ID NO:107, for the locus HUMFIBRA;
SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:72, and SEQ ID NO:73, for the locus HUMTPOX;
SEQ ID NO:74, SEQ ID NO:75, and SEQ ID NO: 104, for the locus D8S1 179; SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:59, SEQ ID NO:60, and
SEQ ID NO:76, for the locus HUMvWFA31 ; SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:98, for the locus HUMCSF1 PO;
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:58, SEQ ID NO:79, and SEQ ID NO:97, for the locus D1 6S539; SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:80, and SEQ ID NO:81 , for the locus D7S820;
SEQ ID NO:3, SEQ ID N0:4, SEQ ID NO:82, and SEQ ID NO:83, for the locus D1 3S317; and
SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:84, and SEQ ID NO:85, for the locus D5S818.
19. The method of claim 17, wherein the set of loci selected in step (a) of the method further comprises at least one additional locus selected from the group of loci consisting of: G475, S159, C221 , and Amelogenin.
20. The method of claim 19, wherein the multiplex amplification reaction is done using at least one oligonucleotide primer having a sequence selected from at least one of the groups of sequences consisting of:
SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:94, when one of the loci in the set is G475;
SEQ ID NO:90, SEQ ID NO:91 , SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, and SEQ ID NO:96, when one of the loci in the set is S1 59;
SEQ ID NO:99 and SEQ ID NO: 100, when one of the loci in the set is C221 ; and SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO: 105, when one of the loci in the set is the Amelogenin locus.
21 . The method of claim 17, wherein the multiplex amplification reaction is a polymerase chain reaction.
22. The method of claim 1 7, wherein the amplified alleles are evaluated by comparing the amplified alleles to a size standard, wherein the size standard is selected from the group of size standards consisting of a DNA marker and a locus-specific allelic ladder.
23. The method of claim 1 7 wherein the at least one DNA sample to be analyzed is prepared from human tissue, wherein the human tissue is selected from the group of human tissue consisting of blood, semen, vaginal cells, hair, saliva, urine, bone, buccal sample, amniotic fluid containing placental cells or fetal cells, and mixtures of any of the tissues listed above.
24. A method of simultaneously identifying the alleles present in a set of loci of from one or more human genomic DNA samples, comprising:
(a) obtaining at least one human genomic DNA sample to be analyzed,
(b) co-amplifying the loci in a set of at least sixteen loci of the human genomic DNA sample in a multiplex amplification reaction, the set of loci comprising D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D1 3S317, D16S539, HUMCSF1 PO, and S1 59, wherein the product of the reaction is a mixture of amplified alleles from each of the co-amplified loci in the set; and
(c) evaluating the amplified alleles in the mixture to determine the alleles present at each of the at least sixteen loci of the human genomic DNA sample.
25. The method of claim 24, wherein the multiplex amplification reaction is done using at least one pair of primers flanking each of the loci in the set of sixteen primers selected in step (b).
26. The method of claim 24, wherein the multiplex amplification reaction is done using at least one primer for at least one locus in the set of at least sixteen loci co-amplified in step (b), wherein the primer has a sequence selected from one of the groups of primer sequences consisting of: SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:101 , and SEQ ID NO: 102, when one of the loci in the set is D18S51 ;
SEQ ID NO:64 and SEQ ID NO:65, for the locus D21 S1 1 ;
SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:66, SEQ ID NO:67, and SEQ ID NO: 103, for the locus HUMTH01 ; SEQ ID NO:68, SEQ ID NO:69, and SEQ ID NO: 106, for the locus
D3S1358;
SEQ ID NO:70, SEQ ID NO:71 ,and SEQ ID NO:107, for the locus HUMFIBRA;
SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:72, and SEQ ID NO:73, for the locus HUMTPOX;
SEQ ID NO:74, SEQ ID NO:75, and SEQ ID NO: 104, for the locus D8S1 179;
SEQ ID NO:39, SEQ ID N0:40, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:76, for the locus HUMvWFA31 ; SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:77, SEQ ID NO:78, and
SEQ ID NO:98, for the locus HUMCSF1 PO;
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:58, SEQ ID NO:79, and SEQ ID NO:97, for the locus D16S539;
SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:80, and SEQ ID NO:81 , for the locus D7S820;
SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:82, and SEQ ID NO:83, for the locus D13S317;
SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:84, and SEQ ID NO:85, for the locus D5S818; SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:94, for the locus
G475; SEQ ID NO:90, SEQ ID NO:91 , SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, and SEQ ID NO:96, for the locus S1 59; and
SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO:105, for the Amelogenin locus.
27. A method of simultaneously identifying the alleles present in a set of loci of from one or more human genomic DNA samples, comprising:
(a) obtaining at least one human genomic DNA sample to be analyzed, (b) co-amplifying the loci in a set of at least sixteen loci of the human genomic DNA sample in a multiplex amplification reaction, the set of loci comprising D3S1358, HUMTH01 , D21 S1 1 , D18S51 , S159, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D1 6S539, HUMCSF1 PO, and C221 , wherein the product of the reaction is a mixture of amplified alleles from each of the co-amplified loci in the set; and (c) evaluating the amplified alleles in the mixture to determine the alleles present at each of the at least sixteen loci of the human genomic DNA sample.
28. The method of claim 27, wherein the multiplex amplification reaction is done using at least one pair of primers flanking each of the loci in the set of sixteen primers selected in step (b).
29. The method of claim 27, wherein the multiplex amplification reaction is done using at least one primer for at least one locus in the set of at least sixteen loci co-amplified in step (b), wherein the primer has a sequence selected from one of the groups of primer sequences consisting of:
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:101 , and SEQ ID NO:102, for the locus D18S51 ;
SEQ ID NO:64 and SEQ ID NO:65, for the locus D21 S1 1 ; SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:66, SEQ ID NO:67, and SEQ ID NO:103, for the locus HUMTH01 ;
SEQ ID NO:68, SEQ ID NO:69, and SEQ ID NO: 106, for the locus D3S1 358; SEQ ID NO:70, SEQ ID NO:71 ,and SEQ ID NO: 107, for the locus
HUMFIBRA;
SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:72, and SEQ ID NO:73, for the locus HUMTPOX;
SEQ ID NO:74, SEQ ID NO:75, and SEQ ID NO: 104, for the locus D8S1 179;
SEQ ID NO:39, SEQ ID N0:40, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:76, for the locus HUMvWFA31 ;
SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:98, for the locus HUMCSF1 PO; SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:58, SEQ ID NO:79, and
SEQ ID NO:97, for the locus D16S539;
SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:80, and SEQ ID NO:81 , for the locus D7S820;
SEQ ID NO:3, SEQ ID N0:4, SEQ ID NO:82, and SEQ ID NO:83, for the locus D13S317;
SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:84, and SEQ ID NO:85, for the locus D5S818;
SEQ ID NO:90, SEQ ID NO:91 , SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, and SEQ ID NO:96, for the locus S159; SEQ ID NO:99 and SEQ ID NO: 100, for the locus C221 ; and
SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO:105, for the Amelogenin locus.
30. A kit for simultaneously analyzing a set of loci of genomic DNA comprising oligonucleotide primers for co-amplifying a set of loci of the genomic DNA to be analyzed, wherein the set of loci comprises at least thirteen short tandem repeat loci which can be co-amplified, and wherein the primers are in one or more containers.
31 . The kit of claim 30, wherein all of the oligonucleotide primers in the kit are in one container.
32. The kit of claim 31 , wherein the genomic DNA is human genomic DNA, and the at least thirteen short tandem repeat loci which can be co-amplified comprise D3S1358, D5S818, D7S820, D8S1 179, D13S317, D16S539, D18S51 , D21 S1 1 , HUMCSF1 PO, HUMFIBRA, HUMTH01 ,
HUMTPOX, and HUMvWFA31 .
33. The kit of claim 30, wherein at least one of the primers for co- amplifying a locus in the set of loci has a sequence selected from one of the groups of primer sequences consisting of:
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:101 , and SEQ ID NO:102, for D18S51 ;
SEQ ID NO:64 and SEQ ID NO:65, for D21 S1 1 ,
SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:38, and SEQ ID NO:103, for HUMTH01
SEQ ID NO:68, SEQ ID NO:69, and SEQ ID NO:106, for D3S1358 SEQ ID NO:70, SEQ ID NO:71 , and SEQ ID NO:107, for HUMFIBRA SEQ ID NO:72 and SEQ ID NO:73, for HUMTPOX SEQ ID NO:74, SEQ ID NO:75, and SEQ ID N0:104, for D8S1 179 SEQ ID NO:76 and SEQ ID N0:40, for HUMvWFA31
SEQ ID N0:77, SEQ ID NO:78, and SEQ ID NO:98, for HUMCSF1 PO SEQ ID NO:29, SEQ ID NO:79, and SEQ ID NO:97, for D16S539 SEQ ID NO:80 and SEQ ID NO:81 , for D7S820 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:82, and SEQ ID NO:83, for D13S317
SEQ ID NO:84 and SEQ ID NO:85, for D5S818.
34. The kit of claim 30, further comprising reagents for at least one multiplex amplification reaction.
35. The kit of claim 30, further comprising a container having an allelic ladder.
36. The kit of claim 35, wherein each rung of the allelic ladder and at least one oligonucleotide primer for each of the loci in the set each have a fluorescent label covalently attached thereto, and at least two of the oligonucleotide primers has a different fluorescent label covalently attached thereto than other primers in the container.
37. A kit for simultaneously analyzing a set of loci of genomic DNA, comprising oligonucleotide primers for co-amplifying a set of loci of the genomic DNA to be analyzed, wherein the primers are in one or more containers, wherein the primers are designed to co-amplify a set of at least sixteen loci which can be co-amplified, comprising D3S1358, HUMTH01 , D21 S1 1 , D18S51 , G475, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO, and S159.
38. A kit for simultaneously analyzing a set of loci of genomic DNA, comprising oligonucleotide primers for co-amplifying a set of loci of the genomic DNA to be analyzed, wherein the primers are in one or more containers, wherein the primers are designed to co-amplify a set of at least sixteen loci which can be co-amplified, comprising D3S1358, HUMTH01 , D21 S1 1 , D18S51 , S159, Amelogenin, HUMvWFA31 , D8S1 179, HUMTPOX, HUMFIBRA, D5S818, D7S820, D13S317, D16S539, HUMCSF1 PO, and C221.
39. A method of simultaneously determining the alleles present in a set of loci from one or more DNA samples, comprising:
(a) obtaining at least one DNA sample to be analyzed,
(b) selecting a set of loci of the DNA sample, comprising at least thirteen short tandem repeat loci which can be co-amplified, wherein at least four of the at least thirteen short tandem repeat loci are selected from the group consisting of:
D3S1539, D4S2368, D5S818, D7S820, D9S930, D10S1239,
D13S317, D14S118, D14S548, D14S562, D16S490, D16S539, D16S753, D17S1298, D17S1299, D19S253,
D20S481, D22S683, HUMCSF1PO, HUMTPOX, HUMTH01, HUMF13A01, HUMBFXIII, HUMLIPOL, HUMvWFA31;
(c) co-amplifying the loci in the set in a multiplex amplification reaction, wherein the product of the reaction is a mixture of amplified alleles from each of the co-amplified loci in the set; and
(d) evaluating the amplified alleles in the mixture to determine the alleles present at each of the loci analyzed in the set within the DNA sample.
40. A kit for simultaneously analyzing a set of loci of genomic DNA, comprising oligonucleotide primers for co-amplifying a set of loci of the genomic DNA to be analyzed, wherein the primers are in one or more containers, wherein the primers are designed to co-amplify a set of at least thirteen loci which can be co-amplified, wherein at least four of the at least thirteen short tandem repeat loci are selected from the group consisting of:
D3S1539, D4S2368, D5S818, D7S820, D9S930, D10S1239,
D13S317, D14S118, D14S548, D14S562, D16S490, D16S539,
D16S753, D17S1298, D17S1299, D19S253, D20S481, D22S683,
HUMCSF1PO, HUMTPOX, HUMTH01, HUMF13A01, HUMBFXIII, HUMLIPOL, HUMvWFA31;
PCT/US1999/027876 1998-11-25 1999-11-24 Multiplex amplification of short tandem repeat loci WO2000031306A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU31034/00A AU774626B2 (en) 1998-11-25 1999-11-24 Multiplex amplification of short tandem repeat loci
CA002352042A CA2352042A1 (en) 1998-11-25 1999-11-24 Multiplex amplification of short tandem repeat loci
BR9915597-4A BR9915597A (en) 1998-11-25 1999-11-24 Multiplex amplification of repeated short tandem loci
JP2000584113A JP5456950B2 (en) 1998-11-25 1999-11-24 Multiplex amplification of short tandem repeat loci
EP99965030A EP1135530B1 (en) 1998-11-25 1999-11-24 Multiplex amplification of short tandem repeat loci
ES99965030T ES2394070T3 (en) 1998-11-25 1999-11-24 Multiplex amplification of locus of short repetitions in tandem
HK01107340.1A HK1036638A1 (en) 1998-11-25 2001-10-19 Multiplex amplification of short tandem repeat loci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/199,542 1998-11-25
US09/199,542 US6479235B1 (en) 1994-09-30 1998-11-25 Multiplex amplification of short tandem repeat loci

Publications (3)

Publication Number Publication Date
WO2000031306A2 true WO2000031306A2 (en) 2000-06-02
WO2000031306A3 WO2000031306A3 (en) 2000-11-09
WO2000031306A9 WO2000031306A9 (en) 2002-08-29

Family

ID=22737974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027876 WO2000031306A2 (en) 1998-11-25 1999-11-24 Multiplex amplification of short tandem repeat loci

Country Status (11)

Country Link
US (1) US6479235B1 (en)
EP (1) EP1135530B1 (en)
JP (2) JP5456950B2 (en)
CN (2) CN101230394A (en)
AU (1) AU774626B2 (en)
BR (1) BR9915597A (en)
CA (1) CA2352042A1 (en)
ES (1) ES2394070T3 (en)
HK (1) HK1036638A1 (en)
PT (1) PT1135530E (en)
WO (1) WO2000031306A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531282B1 (en) 2000-05-30 2003-03-11 Oligotrail, Llc Multiplex amplification and analysis of selected STR loci
FR2836484A1 (en) * 2002-02-25 2003-08-29 Assist Publ Hopitaux De Paris In vitro detection of tumor cells, in a biological sample, uses a highlight of allelic imbalance in insertion-deletion chromosome markers
WO2010146339A1 (en) * 2009-06-15 2010-12-23 Bg Research Ltd Nucleic acid detection
EP2287308A3 (en) * 1998-02-04 2011-06-29 Promega Corporation Materials and methods for identifying and analyzing intermediate tandem repeat DNA markers
WO2012022821A1 (en) * 2010-08-19 2012-02-23 Universidad Del País Vasco Method for obtaining an individual's genetic profile
ES2378204A1 (en) * 2010-08-19 2012-04-10 Universidad Del Pais Vasco Method for obtaining the genetic profile of an individual. (Machine-translation by Google Translate, not legally binding)
ES2378203A1 (en) * 2010-08-19 2012-04-10 Universidad Del Pais Vasco Method for obtaining the genetic profile of an individual. (Machine-translation by Google Translate, not legally binding)
US9310304B2 (en) 2011-05-12 2016-04-12 Netbio, Inc. Methods and compositions for rapid multiplex amplification of STR loci
EP3739064A1 (en) * 2019-05-15 2020-11-18 Biotype GmbH Comparative analysis of microsatellites by capillary electrophoresis (ce) dna profiles

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008771B1 (en) * 1994-09-30 2006-03-07 Promega Corporation Multiplex amplification of short tandem repeat loci
CA2118048C (en) * 1994-09-30 2003-04-08 James W. Schumm Multiplex amplification of short tandem repeat loci
US6617137B2 (en) * 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US7297485B2 (en) * 2001-10-15 2007-11-20 Qiagen Gmbh Method for nucleic acid amplification that results in low amplification bias
CA2468842A1 (en) * 2001-12-11 2003-06-19 Arizona Board Of Regents High resolution typing system for pathogenic e. coli
US7081339B2 (en) * 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
US7445893B2 (en) * 2002-04-12 2008-11-04 Primera Biosystems, Inc. Sampling method for amplification reaction analysis
WO2004009837A2 (en) * 2002-07-19 2004-01-29 Arizona Board Of Regents A high resolution typing system for pathogenic mycobacterium tuberculosum
US20060035236A1 (en) * 2002-07-19 2006-02-16 Keim Paul S DNA fingerprinting for Cannabis sativa (marijuana) using short tandem repeat (STR) markers
WO2004058987A2 (en) * 2002-12-20 2004-07-15 Qiagen Gmbh Nucleic acid amplification
US7955795B2 (en) * 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US20040219533A1 (en) * 2003-04-29 2004-11-04 Jim Davis Biological bar code
US20050026181A1 (en) * 2003-04-29 2005-02-03 Genvault Corporation Bio bar-code
US20050112591A1 (en) * 2003-11-25 2005-05-26 Applera Corporation Novel method for isolating single stranded product
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20060008823A1 (en) * 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
CN1327005C (en) * 2004-12-03 2007-07-18 公安部第二研究所 Complex aplification detecting system of fluorescent marker short tandem repetitive sequence gene locus
EP1863908B1 (en) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transcription and amplification of rna with simultaneous degradation of dna
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US20070027636A1 (en) * 2005-07-29 2007-02-01 Matthew Rabinowitz System and method for using genetic, phentoypic and clinical data to make predictions for clinical or lifestyle decisions
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US20070178501A1 (en) * 2005-12-06 2007-08-02 Matthew Rabinowitz System and method for integrating and validating genotypic, phenotypic and medical information into a database according to a standardized ontology
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
US20080057499A1 (en) * 2006-02-06 2008-03-06 Affymetrix, Inc. Methods for high specificity whole genome amplification and hybridization
US8153372B2 (en) * 2006-12-19 2012-04-10 The Board Of Regents For Oklahoma State University Method for simultaneously determining in a single multiplex reaction gender of donors and quantities of genomic DNA and ratios thereof, presence and extent of DNA degradation, and PCR inhibition within a human DNA sample
CA2984820C (en) 2007-04-04 2021-12-07 Ande Corporation Plastic microfluidic separation and detection platforms
US20090004662A1 (en) * 2007-06-18 2009-01-01 Applera Corporation Method and compositions for nucleic acid amplification
JP5770085B2 (en) 2008-06-30 2015-08-26 ライフ テクノロジーズ コーポレーション Method for direct amplification from crude nucleic acid samples
CN104732118B (en) 2008-08-04 2017-08-22 纳特拉公司 Allele calls the method with ploidy calling
CA2740414A1 (en) * 2008-10-14 2010-04-22 Bioaccel System and method for inferring str allelic genotype from snps
WO2010147654A2 (en) 2009-06-15 2010-12-23 Netbio Inc. Improved methods for forensic dna quantitation
EP2290004B1 (en) 2009-07-31 2016-08-31 Ems-Patent Ag Polyamide blend moulding material
CN101691607B (en) * 2009-08-14 2013-07-17 河北医科大学 Method and reagent kit for testing human gene typing by labeling mini-STR (short tandem repeats) with fluorescence
ES2640776T3 (en) 2009-09-30 2017-11-06 Natera, Inc. Methods for non-invasively calling prenatal ploidy
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
CA2798758C (en) 2010-05-18 2019-05-07 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
AU2011348100B2 (en) 2010-12-22 2016-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
CA2824387C (en) 2011-02-09 2019-09-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
ES2416836B1 (en) * 2011-12-29 2014-04-07 Universidad Del País Vasco METHOD FOR OBTAINING THE GENETIC PROFILE OF AN INDIVIDUAL
CN102586433B (en) * 2012-02-14 2014-01-29 北京科聆金仪生物技术有限公司 Deafness predisposing gene 12S rRNA (ribosomal ribonucleic acid) 1494C>T fluorescence detection kit and application thereof
CN102605052B (en) * 2012-02-14 2014-01-29 北京科聆金仪生物技术有限公司 Fluorescence detection kit for detecting deafness susceptibility gene GJB2 235delC and application of fluorescence detection kit
CN104685064A (en) * 2012-07-24 2015-06-03 纳特拉公司 Highly multiplex PCR methods and compositions
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US9499870B2 (en) 2013-09-27 2016-11-22 Natera, Inc. Cell free DNA diagnostic testing standards
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
EP3134541B1 (en) 2014-04-21 2020-08-19 Natera, Inc. Detecting copy number variations (cnv) of chromosomal segments in cancer
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
WO2017087724A1 (en) 2015-11-17 2017-05-26 Omniome, Inc. Methods for determining sequence profiles
US10822647B2 (en) 2016-07-12 2020-11-03 Biodynamics S.R.L. Methods for using long ssDNA polynucleotides as primers (superprimers) in PCR assays
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
EP3585889A1 (en) 2017-02-21 2020-01-01 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
CN107012225B (en) * 2017-04-20 2020-10-09 司法鉴定科学研究院 STR locus detection kit and detection method based on high-throughput sequencing
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN110229871B (en) * 2019-04-26 2023-06-23 上海晶准生物医药有限公司 Preparation method of universal short tandem repeat sequence allele ladder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8606719D0 (en) 1986-03-19 1986-04-23 Lister Preventive Med Genetic probes
US4963663A (en) 1988-12-23 1990-10-16 University Of Utah Genetic identification employing DNA probes of variable number tandem repeat loci
WO1989007658A1 (en) 1988-02-18 1989-08-24 University Of Utah Genetic identification employing dna probes of variable number tandem repeat loci
US5766847A (en) 1988-10-11 1998-06-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for analyzing length polymorphisms in DNA regions
US5582979A (en) 1989-04-21 1996-12-10 Marshfield Clinic Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5364759B2 (en) * 1991-01-31 1999-07-20 Baylor College Medicine Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats
WO1993018177A1 (en) 1992-03-13 1993-09-16 The Children's Hospital Of Philadelphia Diagnosis of cystic fibrosis using allele specific multiplex polymerase chain reactions
WO1993018178A1 (en) 1992-03-13 1993-09-16 The Children's Hospital Of Philadelphia DIAGNOSIS OF β-THALASSEMIA USING A MULTIPLEX AMPLIFICATION REFRACTORY MUTATION SYSTEM
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5599666A (en) 1994-03-28 1997-02-04 Promega Corporation Allelic ladders for short tandem repeat loci
US5843660A (en) 1994-09-30 1998-12-01 Promega Corporation Multiplex amplification of short tandem repeat loci
GB9625124D0 (en) 1996-12-03 1997-01-22 Sec Dep Of The Home Department Improvements in and relating to identification
US6013444A (en) * 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUDOWLE, BRUCE; MORETTI, TAMYRA, SPEAKER ABSTRACTS; 9TH INTERNATIONAL SYMPOSIUM ON HUMAN IDENTIFICATION, 7 October 1998 (1998-10-07), pages 7 - 8

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287307A3 (en) * 1998-02-04 2011-06-29 Promega Corporation Materials and methods for identifying and analyzing intermediate tandem repeat DNA markers
EP2287308A3 (en) * 1998-02-04 2011-06-29 Promega Corporation Materials and methods for identifying and analyzing intermediate tandem repeat DNA markers
US6531282B1 (en) 2000-05-30 2003-03-11 Oligotrail, Llc Multiplex amplification and analysis of selected STR loci
WO2003072823A3 (en) * 2002-02-25 2004-04-08 Assist Publ Hopitaux De Paris Method for in vitro detection of cancers by highlighting allelic imbalances in insertion/deletion markers
WO2003072823A2 (en) * 2002-02-25 2003-09-04 Assistance Publique-Hopitaux De Paris Method for in vitro detection of cancers by highlighting allelic imbalances in insertion/deletion markers
FR2836484A1 (en) * 2002-02-25 2003-08-29 Assist Publ Hopitaux De Paris In vitro detection of tumor cells, in a biological sample, uses a highlight of allelic imbalance in insertion-deletion chromosome markers
WO2010146339A1 (en) * 2009-06-15 2010-12-23 Bg Research Ltd Nucleic acid detection
CN102803506A (en) * 2009-06-15 2012-11-28 Bg研究有限公司 Nucleic acid detection
WO2012022821A1 (en) * 2010-08-19 2012-02-23 Universidad Del País Vasco Method for obtaining an individual's genetic profile
ES2378204A1 (en) * 2010-08-19 2012-04-10 Universidad Del Pais Vasco Method for obtaining the genetic profile of an individual. (Machine-translation by Google Translate, not legally binding)
ES2378203A1 (en) * 2010-08-19 2012-04-10 Universidad Del Pais Vasco Method for obtaining the genetic profile of an individual. (Machine-translation by Google Translate, not legally binding)
US9310304B2 (en) 2011-05-12 2016-04-12 Netbio, Inc. Methods and compositions for rapid multiplex amplification of STR loci
US11022555B2 (en) 2011-05-12 2021-06-01 Ande Corporation Methods and compositions for rapid multiplex application of STR loci
EP3739064A1 (en) * 2019-05-15 2020-11-18 Biotype GmbH Comparative analysis of microsatellites by capillary electrophoresis (ce) dna profiles
WO2020229461A1 (en) * 2019-05-15 2020-11-19 Biotype Gmbh Comparative analysis of microsatellites by capillary electrophoresis (ce) dna profiles

Also Published As

Publication number Publication date
JP2010081944A (en) 2010-04-15
CA2352042A1 (en) 2000-06-02
ES2394070T3 (en) 2013-01-16
CN100366753C (en) 2008-02-06
JP2002530121A (en) 2002-09-17
AU774626B2 (en) 2004-07-01
PT1135530E (en) 2012-12-18
US6479235B1 (en) 2002-11-12
AU3103400A (en) 2000-06-13
EP1135530A2 (en) 2001-09-26
BR9915597A (en) 2001-10-23
JP5711887B2 (en) 2015-05-07
CN101230394A (en) 2008-07-30
WO2000031306A9 (en) 2002-08-29
HK1036638A1 (en) 2002-01-11
JP5456950B2 (en) 2014-04-02
CN1332805A (en) 2002-01-23
WO2000031306A3 (en) 2000-11-09
EP1135530B1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
US7008771B1 (en) Multiplex amplification of short tandem repeat loci
JP5711887B2 (en) Multiplex amplification of short tandem repeat loci
US5843660A (en) Multiplex amplification of short tandem repeat loci
EP2640848A1 (en) Methods and kits for multiplex amplification of short tandem repeat loci
Micka et al. Validation of multiplex polymorphic STR amplification sets developed for personal identification applications
Gabriel et al. Population variation of human mitochondrial DNA hypervariable regions I and II in 105 Croatian individuals demonstrated by immobilized sequence-specific oligonucleotide probe analysis
US9260757B2 (en) Human single nucleotide polymorphisms
EP2789693B1 (en) Amelogenin SNP on chromosome X
CN113234838A (en) Primer pair, product and method for identifying sheep FecB genotype by high-resolution melting curve
CN109312397A (en) The identification of Penta E locus polymorphic human body
MXPA98008487A (en) Multiplex amplification of repetition sites in tandem cor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813729.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 31034/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2352042

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2352042

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 584113

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 1999965030

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1999965030

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999965030

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/12-12/12; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWG Wipo information: grant in national office

Ref document number: 31034/00

Country of ref document: AU